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ABSTRACT  
Changing Dynamics of Opioid Overdoses in West Virginia and Impact of Medication for Opioid Use 
Disorder and Recurrence of Overdose on Reducing Mortality among West Virginia Medicaid 
Beneficiaries 
 
Zheng Dai 
Background 
With increasing number of opioid overdoses in West Virginia (WV) in recent years and limited number of 
people receiving treatment, the dissertation study aims to better understand fatal overdose problems in 
WV and the impact of medication for opioid use disorder (MOUD) in preventing overdose deaths. 
Method 
WV drug-related deaths from 2005 to 2018 was used to describe the involvement of fentanyl and FAs. 
WV Medicaid claim data was analyzed to describe the recurrent opioid overdose and the changes in 
receipt of MOUD. Further, a Medicaid opioid overdose cohort was created to evaluate the effect of 
occurrence of recurrent overdose and receipt of MOUD on survival outcomes following a non-fatal 
overdose after 12 months. 
Results 
Fentanyl and FAs were drastically increasingly involved in WV fatal overdoses. Overall, only about 5-
10% of people who experienced an opioid overdose received MOUD at any time. Compared with no 
MOUD, those who received MOUD were associated with non-significant increase of all-cause mortality 
(adjusted hazard ratio 1.14), and occurrence of recurrent overdose was associated with non-significant 
increase of all-cause mortality (adjusted hazard ratio 1.54).  
Conclusion 
Starting 2015, drug involvement in the deaths changed from predominantly prescription opioids to 
fentanyl and new identified FAs. MOUD is likely to be effective in lowering mortality risk in WV. 
However, small sample size and limited follow up period prevented us from reaching sufficient statistical 
power. Future research with more recent years’ Medicaid data are needed to guide the timely receipt of 
MOUD for the patients in urgent need. 
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Chapter 1. Introduction 
1.1 Background 
Unintentional injuries, which is the third leading cause of death, have been increasing since 2014 
despite the overall decreasing trend of other top causes of death 1(Xu et al. 2016). The overall 
mortality rate for unintentional drug poisonings in the United States (US) grew exponentially in 
recent years 2(Jalal et al. 2018). There were an estimated 72,000 deaths due to drug poisoning in 
2017 3(Hedegaard et al. 2018), which exceeds those from motor vehicle crashes, gun violence 
and even HIV at the height of the 1990s HIV epidemic 4(Ciccarone 2019). Opioids are the main 
driver of drastically increasing drug overdose deaths over the last 20 years, accounting for over 
two-thirds of drug overdose death and resulting in a substantial public health burden of about 
five years of life lost per 1,000 people 5(Gomes et al. 2018). Further, an estimated over 2 million 
people aged over 12 were diagnosed as opioid use disorder (OUD) patients according to a 
Substance Abuse and Mental Health Services Administration (SAMHSA) report in 2017 
6(SAMHSA, 2017).  
West Virginia (WV), which is a predominantly rural state in Appalachia, is at the epicenter of the 
US national opioid overdose crisis characterized by overdose and relapses 7(Wolf et al., 2020). 
WV leads the nation in drug overdose mortality with the highest mortality rate of 58 per 100,000 
population as of 2017, almost 3 times the US average 8(Scholl et al., 2019). Across all states, 
WV had the third lowest median household income, third highest unemployment rate, seventh 
highest poverty rate, eighth highest prescribing rates for opioids, and tenth lowest rate for people 
who completed high school in 2017 9,10(CDC 2018; United States Census Bureau 2017). The 
current opioid crisis has strained the capacity of health care and social service resources and 
taken a significant toll on individuals, families, communities, and counties in WV 11,12(Saloner et 
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al. 2019; Carre et al., 2017). In addition, West Virginia state law does not require overdose as a 
reportable condition and overdose reporting period is quarterly, making tracing overdose even 
hard (Davis et al., 2018)13. 
1.1.1 Fentanyl Era 
The substance use patterns have changed drastically over time. The US has gone through a triple 
wave epidemic of overdose deaths from three classes of opioids: 1) prescription opioids such as 
oxycodone, hydrocodone, methadone, etc., 2) heroin, and 3) synthetic opioids other than 
methadone, mainly fentanyl and fentanyl analogs 14(Ciccarone 2017). In the first wave, death 
rates for prescription drugs were greater among rural than urban populations. To curb the first 
wave of opioid epidemic, continuous efforts from national and state levels were committed, 
including restrictions on opioids prescriptions and establishment of PDMP nationwide. However, 
one study suggested that as prescription opioid use has waned, concurrent heroin abuse has 
increased, with distinct regional variations 15(Compton et al., 2016). The second and third wave 
predominantly affected the Northeast (including Mid-Atlantic) and the Midwest (including 
Appalachia) 2(Jalal et al. 2018). It is postulated that with greater difficulty obtaining prescription 
opioids, alongside widely available heroin supply, the drug users simply transmitted to heroin 
use and then leading to the increased illicitly manufactured fentanyl IMF use 16(Hempstead and 
Yildirim 2014). In summary, the current state of the opioid crisis is attributable to excessive 
prescribing behaviors, widespread availability of inexpensive heroin, and an increase in use of 
highly potent fentanyl and its analogs 17,18(Armenian 2017; Suzuki and El-Haddad 2017).  
Fentanyl and carfentanil, respectively, are approximately 50-100 and 10,000 times more potent 
than prescription morphine, and have been identified in adulterated prescription drugs, heroin, 
cocaine, and methamphetamine 9,19,20(Arens 2016; Mars 2017; CDC 2018). Relative uncertainty 
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regarding purity of compounds has been largely ignored among illcit drug users, resulting in 
deaths due to misusing or abusing these substances 21(Frank and Pollack 2017). National data 
indicates that synthetic opioids, mostly fentanyl and FAs, were involved in more than half of 
opioid overdose deaths occurring in the 12-months ending November 2017 9(CDC 2018). 
It is postulated that the greater penetration of fentanyl is part of the reasons why higher overdose 
risk was observed in the Northeast and Midwest of the States, compared to the South 22(Morgan 
et al. 2019). Fentanyl and FA-related deaths have increased dramatically with much of the 
fentanyl identified consisting of IMF 9,17,18(Armenian et al. 2017; Suzuki and El-Haddad 2017; 
CDC 2018). Potent FAs such as carfentanil (veterinary drug) and furanyl fentanyl maintain 
fentanyl’s pharmacologic effects while being difficult to detect with standard toxicological 
testing (Armenian et al. 2017; Suzuki and El-Haddad 2017). Fentanyl and carfentanil are such 
potent opioids or benzodiazepines that even a small amount of exposure can cause opioid 
overdose, coma, or death, which pose serious health threats to the public 17,18,23,24(Armenian et al. 
2017; Suzuki and El-Haddad 2017; Kuehn., 2010; Park et al., 2020). Combining IMF/FAs with 
other opioids increases the overdose risk by potentiating respiratory and central nervous system 
depression, often resulting in rapidly occurring death 25,26(Fox et al. 2018; Slavova et al. 2017). 
To make matters worse, the “fentanyl high” lasts a much shorter time than heroin’s does, 
suggesting injection drug users are more likely to inject more frequently, which makes them 
more susceptible to infectious diseases and overdose 17,18(Armenian et al. 2017; Suzuki and El-
Haddad 2017). The OUD population may fall into a potentially fatal drug use behavior with 
more mixed drug use and more injections.  
1.1.2 West Virginia Medicaid Population 
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Medicaid programs effectively respond to the opioid crisis by expanding treatment coverage and 
reforming treatment delivery systems 27(Barnes et al., 2020). Approximately 29% of the WV 
population are covered by Medicaid, and this makes WV rank highest in the nation in terms of 
proportion of population covered 28(Kaiser Family Foundation 2018). According to West 
Virginia Department of Health and Human Resources Bureau (WVDHHR)29, drug overdose 
decedents were much more likely to have Medicaid (71%) in the 12 months prior to their death 
as compared to West Virginia’s adult population aged 19-64 (23%). Specifically, of those 
decedents with Medicaid, 81% utilized the benefit within 12 months prior to their date of death, 
excluding those decedents who only used the benefit within 48 hours before death29. As for ED 
visits, 68% of decedents with Medicaid had at least one ED visit in the 12 months prior to death. 
Medicaid enrollees have an estimated 3-times higher risk of opioid overdose (Sharp and Melnik, 
2015)30 and has been identified as a high-risk population for fatal opioid overdose by Centers for 
Disease Control and Prevention (CDC) (Garg et al., 2017; Stoove et al., 2009)31,32. In addition, 
the WV DHHR Bureau for Medical Services (BMS) gained approval in 2014 for a Medicaid 
Section 1115 waiver to develop a continuum of care for individuals with substance use issues. 
Expansion of Medicaid started in 2014, and served as an important step in increasing 
accessibility of MOUD for persons with substance abuse disorder 29,33(WVDHHR 2017; Sharp et 
al. 2018).  
Unfortunately, the need for care far exceeds the current treatment infrastructure in West Virginia, 
resulting in long waiting lists, and eventual overdose for many persons actively seeking 
treatment 34(Pollini et al. 2006). Worse, patients are also suffering risks from many drug-related 
medical conditions, such as viral infections (HIV or hepatitis), suicide, alcohol use disorder, 
respiratory diseases, circulatory diseases and skin infections (Bohnert et al., 2012; Suffoletto and 
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Aeigler et al., 2020)35,36. Private care facilities are a potential option, but often too expensive for 
persons living in West Virginia where the median annual family income is $42, 644 10(United 
States Census Bureau 2017) and the average cost of treatment can range from $2,000 to $15,682 
37(Jones et al. 2009). Rural transportation also presents a difficult issue as over 50% of West 
Virginia’s population is classified as rural 10(United States Census Bureau 2017), restricting 
state/city managed transportation services.  
1.1.3 Medication for Opioid Use Disorder and Treatment Barriers 
To address increasing opioid overdoses and cure increasing numbers of OUD patients, evidence-
based and appropriate clinical interventions and treatment models to prevent opioid overdose 
mortality are urgently needed 38(Wakeman 2019). Medication for opioid use disorder (MOUD) 
regimens utilizing three FDA approved medications (methadone, buprenorphine, and naltrexone) 
are promising treatment options in reducing drug use, compulsive drug seeking, substance use 
relapse, and overdose 33,39-46(Sharp et al. 2018; Schwartz et al. 2013; Rudd 2016; Banta-Green et 
al. 2017; Zoorob 2019; Mancher and Leshner, 2019; Kimber et al., 2015; Volkow et al., 2014; 
Ma et al.,2018). Combined with behavioral therapy (e.g., cognitive-behavioral therapy or 
contingency management) and counseling or by itself, MOUD has proven to be effective in 
reducing drug-related outcomes, including ED visits, hospitalization and mortality 47-
50(Alexandridis et al. 2018; Barnett 2009; Larochelle et al., 2018; Larochelle et al., 2016), as well 
as getting people back to productive functioning in the family and workplace. However, effective 
but not perfect, there haven’t been systematic evaluation of MOUD effectiveness on WV 
population, which is quite different from other populations in the States, as we have explained 
previously.  
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For buprenorphine treatment, another reason why the timing of initiation of MOUD is critical is 
that patients must be in active opioid withdrawal to initiate the medication safely. The prognosis 
during or after the treatment would be better when induction is offered as soon as possible 
(Sigmon et al., 2016; Clausen et al., 2008)51,52. However, many clinicians require the patients to 
meet certain criteria before offering them buprenorphine, such as active engagement in 
counseling, which may result in delays (Martin et al., 2018)53. A study demonstrated the 
importance of the timing of initiation of methadone treatment by showing that the mortality risk 
for persons at waiting list is 10 times greater than for those who initiate treatment as soon as 
possible (Peles et al., 2013)54. Similarly for naltrexone, patients need to go through a few days of 
opioid abstinence before the initiation of medication. The induction period is critically for a 
successful initiation of naltrexone, and many patients failed to pass the induction period which 
leads to early drop out and readily relapse (Lee et al., 2015; Gordon et al., 2015).55,56 
However, the massive “treatment gap” in accessing pharmacotherapy of OUD remains a 
challenge -- only one third of OUD patients identified from WV Medicaid received 
buprenorphine in early 2014 57(Koyawala et al., 2019). Nationally in 2017, only one out of nine 
SUD patients received MOUD58. Among those receiving treatment, approximately one third of 
them dropped out within 90 days (suggesting limited effectiveness)58-61. 
According to the 2017 National Survey on Drug Use and Health62, for those underserved OUD 
populations who perceived a need for treatment but not receiving MOUD, some of them had 
difficulty accessing treatment resources (no health care coverage) and suffer from stigma 
towards drug-using (negative impression from neighbors, communities and health care 
providers). Additional barriers include shortage of providers who offer MOUD (long waiting 
list), limited health insurance coverage for OUD treatment (Methadone not covered in West 
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Virginia before 2018), and weak data on the quality of MOUD treatment evaluation62. Further, 
social and support care services that are necessary for a proper continuum of care are not widely 
available, resulting in poor treatment compliances, high drop out and readmission rates, and 
frequently happened relapses, leading to negative health outcomes including mortality58. 
1.1.4 Recurrent Opioid Overdose 
In general, persons experiencing nonfatal overdose are at increased risk of overdose death 
(Coffin et al. 2007; Colledge et al., 2019; Thylstrup et al., 2020)63-65. This risk is further 
intensifying in states like West Virginia experiencing geographic isolation 66(Hall et al. 2008), 
massive opioid prescriptions (Okie, 2010; Paulozzi et al., 2011; Boyle et al., 2017)67-69, high 
rates of psychiatric conditions (Webster et al., 2017; Brady et al., 2017)70,71, and having limited 
medical resources, resulting in gaps between need for sustainable treatment and the state’s 
capacity to deliver these options (Jones et al. 2015)72. Therefore, it is of great public health 
importance to rapidly address the opioid overdose problem in WV. This study addressed the WV 
overdose problem through development of a series of studies focusing on drug-related deaths in 
Forensic Drug Data (FDD) and persons with opioid use disorder in Medicaid claims data. 
An earlier estimation done over a decade ago suggested that on average an overdose decedent 
experienced 30 recurrent overdoses 73(Frazier et al. 2017). However, a recent study conducted in 
Kentucky demonstrated that fentanyl overdose has a strikingly low ratio of ED visits to deaths 
(Slavova et al. 2017)26. Another study conducted in Massachusetts showed that the ratio of 
nonfatal to fatal overdoses has dropped to less than 12 in 2015 (Massachusetts Department of 
Public Health, 2017)74. The study suggested that in the current fentanyl era, the nonfatal episode 
represents an important rescue window (Hasegawa et al., 2017)75. Fentanyl overdoses occur 
much more rapidly than heroin or prescription opioids overdoses, resulting in death within 
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seconds (Dai et al., 2019)76. A few minutes of oxygen deprivation, an overdose may lead to 
permanent brain damage or death (Zibbell et al. 2020)77. Therefore, any presence of overdose is a 
potential opportunity for initiating treatment to reduce the chances of a recurrent overdose or 
even fatal overdose 73(Frazier et al. 2017). People who have one ov2erdose are more likely to 
have a following one (Olfson et al. 2018; Darke et al., 2007; Lowder et al., 2020; Havens et al., 
2011)78-82, and missing any chance for intervention would be potentially lethal for the overdose 
population, specifically when super-potent fentanyl or FAs are increasingly involved in 
overdoses. 
1.2 Purpose Statement 
This study is the first to comprehensively describe the current synthetic opioid problem, 
especially fentanyl and/or fentanyl analog-related death in WV. An in-depth description of 
characteristics of overdose and OUD patients among WV Medicaid population is very valuable 
for future policy making and treatment improvement. More importantly, another innovative 
aspect to the project is the application of survival methodologies alongside an in depth 
investigation of MOUD effectiveness in a West Virginia Medicaid population. In the case of 
treating OUD patients, the challenge is to provide the right treatment to the right patients at the 
right time. However, given there are long waiting list to receive MOUD due to limited treatment 
resources and low treatment retention rate, the survival outcome of OUD patients is of great 
concern. To date, no studies have incorporated comprehensive time-dependent MOUD 
information modelling to assess the patients’ survival rates after the treatment. Cox proportional 
hazard models are appropriate to incorporate time-dependent MOUD and recorded non-fatal 
overdose information to identify the optimal time for effective intervention. Results from this 
study are expected to inform policy due to the fact that ~29% of WV’s population are Medicaid 
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beneficiaries, and given the recent efforts by state agencies to expand MOUD access. The 
research group, including professional epidemiologists in drug overdose prevention, statisticians 
specialized in survival analysis and pharmacists with years’ experience analyzing Medicaid data, 
is truly multidisciplinary. 
Results from this study will specifically add to the literature in the following three aspects: 
1. Increase understanding of evolving poly-substance use patterns including fentanyl and 
fentanyl analogs among West Virginia drug use population. 
2. Examine recurrent opioid overdose and how changes in receipt of MOUD following a non-
fatal overdose influence risk of mortality among the WV Medicaid population.  
3. Identify associations between time-dependent MOUD and mortality among a WV Medicaid 
overdose cohort, adjusting for recurrent overdose and other risk factors. 
The long-term goal of the study is to provide evidence to inform treatment expansion and policy 
reform efforts in West Virginia to timely deliver MOUD to fulfill patients’ urgent needs. The 
central hypothesis is that the differences in survival rates are time-dependent over the initiation 
of treatment, length of treatment, and recurrent overdose, controlling for patients’ demographics, 
medical conditions, and drug use. To address the goals of our study, the following specific aims 
were formed as below. 
1.3 Specific Aims 
Sample design 
For Aim 1, to describe fatal overdose problems in West Virginia and its relation to fentanyl and 
other opioids, data from forensic drug database (FDD) was analyzed to achieve the goal. FDD 
was created in 2005 in collaboration with the West Virginia Office of the Chief Medical 
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Examiner (WVOCME) to compile data from all WV drug-related deaths. West Virginia uses a 
centralized medical examiner system and the WVOCME maintains files for WV deaths. Drug-
related death data used in this study was extracted from 2005 through June 2018. Deaths 
included those in which overdose was the immediate cause of death, or a transportation-related 
or other injury (e.g., motor vehicle, ATV, drowning, etc.) was the immediate cause of death but 
drugs were believed to be significant contributors to death. For example, fentanyl or FA-related 
deaths were defined as if one or more of these substances was found during postmortem 
toxicology testing and identified as a cause of or contributor to death in Parts I or II of the death 
certificate. All drug-related deaths in WV from 2005 to June 2018 were included into the 
analyses. West Virginia residence who died out of WV were not included. The deaths with 
substance identified but not ruled to cause or contribute to the death were excluded. For example, 
natural deaths from cardiovascular pathogen with marijuana identified and administered days 
ago were excluded.  
For Aim 2 and 3, to identify association between time-dependent MOUD and recurrent overdose 
or all-cause mortality, a WV Medicaid overdose cohort was selected and analyzed for survival 
outcome. WV Medicaid created a Common Data Model (CDM) to incorporate an extensively 
cleaned subset of WV Medicaid data that was designed to study opioid-related measures.  The 
CDM included WV Medicaid data from 2014 to 2016 for persons aged 18-64 and excluded 
about 20% of people who had dual-eligibility with Medicare, as Medicare is the primary payer 
and Medicaid does not include all claims from this group. An overdose cohort was then created 
from CDM by selecting continuously enrolled persons ages 18 to 64 with at least one nonfatal 
overdose event identified by ICD codes (Appendix A, ICD-9: 965.00-965.02, 965.09, E850.0-
E850.2 or ICD-10: X40-X44, X60-X64, X85, Y10-Y14) from emergency department (ED) visits 
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or hospitalization. Multiple opioid overdoses that occurred during one hospitalization interval 
(admission and discharge date) were counted as one overdose event. Two overdoses recorded 
within two days were also accounted as one overdose event. Thus, a recurrent overdose event 
was defined as one occurring at least two days after the previous overdose (avoid potential carry-
on effect from previous overdose). Among those who had at least 12 months length of 
observation overdose free, the first nonfatal overdose identified was marked as the index 
overdose. The retrospective cohort follow-up starts with the index overdose, and ends with death 
or with beneficiaries dropping out within 12 months after the index overdose. The cohort 
excluded those who died within 30 days of index overdose (make sure every subject had at least 
one-month follow up) and patients with any cancer diagnosis (avoid confounding effect from 
cancer) at any time of cohort. The ICD -9 and ICD-10 codes used to identify cancer were listed 
in Appendix A. Missing values were checked for age and gender and no one was excluded for 
this reason. 
Predictors 
For Aim 1, demographic characteristics, co-intoxicants as well as medical conditions were 
extracted from FDD directly. Each FDD case includes demographic information (e.g., age, sex, 
race, weight, height, date of death, zip code of residence), cause and manner of death, toxicology 
findings (e.g., drugs identified, concentrations, postmortem interval), whether a prescription was 
present within the past 30 days for controlled substances, autopsy findings, and medical history. 
For Aim 2 and 3, demographic characteristics, including age, sex, race/ ethnicity and enrollment 
category, were extracted from the Medicaid enrollment files. Age was recorded at the time of 
index overdose. Start and end date of each overdose and any other diagnosis were extracted from 
inpatient and outpatient data files. Date and duration of each prescription were extracted from 
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pharmacy data files. For medication not applicable for prescription, including injectable 
naltrexone and implantable buprenorphine, the date and duration of each treatment episode were 
extracted from professional data files. In the Cox model, all medical conditions and prescriptions 
were extracted at the baseline (index overdose).  
This study was reviewed and approved by the Institutional Review Board (protocol number: 
1711862183A001) at the West Virginia University, Morgantown, WV.  
Analysis Plan 
For Aim 1, data management and analysis were conducted using SAS (version 9.4, SAS 
Institute, Cary, NC). For Aim 2 and 3, data management and analysis were conducted using 
Enterprise Grid software (version 5.1, SAS Institute, Cary, NC). Significance level was set to 
0.05 for all tests unless otherwise specified. 
Specific Aim 1: Describe fatal overdose problems in West Virginia and its relation to 
fentanyl and other opioids. 
Hypothesis 1: Fentanyl or FAs-related deaths have different demographic and toxicological 
characteristics than those deaths with prescription opioids involved.  
Descriptive analyses were used to characterize the drug-related deaths. T-tests and Chi-square 
tests were used for continuous and categorical data comparisons, respectively. Co-intoxicants in 
fentanyl and FA-related deaths are compared through the 2005–2014 and the 2015–2017 time 
periods because the number of fentanyl and FA-related deaths did not increase substantially until 
2015. The number of drugs with a valid prescription (defined as a prescription present within 30 
days prior to death) was determined through use of the WV CSMP. Comorbidities identified 
through autopsy reports and other information in decedents files are defined as follows: 
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cardiovascular (cardiomyopathy, cardiomegaly, hypertrophy, hypertensive cardiovascular 
disease, ischemic heart disease, atherosclerotic coronary artery disease, cardiac disease, heart 
failure, myocardial infarction), psychiatric other than substance abuse disorder (Alzheimer's 
disease, anxiety disorder, attention deficit hyperactivity disorder, bipolar affective disorder, 
chronic fatigue, delusional disorder, dementia, depression, mania, mental/behavioral disorders, 
obsessive-compulsive disorder, panic attacks, posttraumatic stress disorder, psychosis, 
schizophrenia, suicide attempts/ideation, self-mutilation behavior), pulmonary (asthma, sleep 
apnea, chronic obstructive pulmonary disease, pneumoconiosis), hepatic (hepatitis, cirrhosis, 
alcoholic/other liver disease, hepatic necrosis, hepatic failure), pain (ankylosing spondylitis, 
migraine/headache syndromes, arthritis/polyarthritis/rheumatoid arthritis/ osteoarthritis, systemic 
lupus, systemic sclerosis, neuropathy pain, acute pain, chronic pain, fibromyalgia, pancreatitis, 
systemic lupus, hip fracture), and history of substance abuse (drug, alcohol or other substance).  
Specific Aim 2: Examine recurrent opioid overdose and the changes of receipt of 
Medication for Opioid Use Disorder (MOUD) following a non-fatal overdose among the 
West Virginia (WV) Medicaid population. 
Hypothesis 2:  Proportion of receipt of MOUD remains low even after a non-fatal overdose. 
Sub aims include 1) characterizing overdose population among WV Medicaid beneficiaries, 
stratified by the number of overdoses and MOUD receipt; 2) examining occurrence of recurrent 
opioid overdose, change of receipt of MOUD and medication use before and after the index 
overdose. 
The primary outcomes in this aim are recurrent overdose and receipt of MOUD. The receipt of 
MOUD was identified from both pharmacy datasets using National Drug Codes (NDC), and 
from inpatient and outpatient datasets using procedure codes. First, the descriptive statistical 
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analysis were performed to describe the opioid overdose cohort. Number and percentage were 
reported for categorical variables. Demographic characteristics including age, gender, and 
Medicaid eligibility category were analyzed. The number and frequency of overdose events, the 
monthly receipt of MOUD, the number and type of frequently present mental health conditions 
(including anxiety, bipolar, depression, alcohol use disorder, and substance use disorder) 
identified by ICD-9 or ICD-10 codes were also analyzed. Descriptive analyses compared 
medication (including opioid analgesics and benzodiazepines) use patterns before and after the 
index overdose. 
Specific Aim 3: Identify associations between time-dependent MOUD and all-cause 
mortality/ opioid-specific mortality among a WV Medicaid overdose cohort, adjusting for 
recurrent overdose and other risk factors.  
Hypothesis 3: Delay in initiation of MOUD after occurrence of first nonfatal overdose negatively 
affect patients’ survival rates, which is also mediated by recurrent overdose events. 
The primary outcome of interests in this aim are all-cause mortality and opioid-specific mortality 
in the 12-month follow up. The main exposures were receipt of MOUD and recurrent overdose. 
The first date of receipt of MOUD was identified and compared to the date of index overdose to 
determine the presence or absence of baseline status. Duration of MOUD was calculated as 
cumulative days in treatment and then dichotomized by the median value. The types of 
medication use were separated into three groups: buprenorphine use only, naltrexone use only, 
and mixed group. 
Potential confounding variables were also examined. Patients’ age and gender were obtained 
from Medicaid enrollment files. Age was categorized into 3 groups: 18 to 29 years, 30 to 44 
years and 45 year or older. Post index overdose prescription of opioids and benzodiazepines 
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were also identified and dichotomized into presence or absence. Psychiatric diagnosis including 
anxiety, depression, bipolar, alcohol use disorder and other drug use disorder (stimulants, 
cannabis, etc. related disorder) were also identified. 
Kaplan–Meier method was used to examine survival trends (all-cause mortality and opioid-
specific mortality) by receipt of MOUD and number of overdoses. A log-rank test was used to 
assess the difference of time-to-events between subgroups.  
Univariate and multivariable Cox proportional hazard models were applied to evaluate MOUD 
effectiveness on reducing both all-cause mortality and opioid-specific mortality, while adjusting 
for other important confounders, including presence of opioids, benzodiazepines, anxiety, 
depression, bipolar, alcohol use disorder, and other drug use disorder. Multivariable models were 
developed in a sequential approach, by first only modelling MOUD presence or absence, and 
then specifically modelling the subsets with MOUD presence. Timing of initiation of MOUD, 
duration of MOUD and recurrence of overdose were added into the subgroup Cox model to have 
a comprehensive evaluation of MOUD through survival approach.  
We expect to determine an optimal intervention time and treatment plan through this analysis. 
The clinical significance of this aim is to evaluate patients’ survival rates, taking into account 
comprehensive time-dependent MOUD and time-dependent recurrent overdose events. It is 
essential to identify patients who are in urgent need for MOUD, provide them priority for the 
right treatment, and maintain them in the treatment long enough to improve the long-term 
survival outcome.  
Limitations 
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Although Medicaid claim data captures over 70% of West Virginia overdoses, a major limitation 
of data in the study time period (2014 – 2016) is that methadone was not covered by Medicaid. 
In other words, this study was unable to evaluate effectiveness of methadone in treating OUD 
patients and preventing deaths. However, few clinics offer methadone treatment in WV and most 
of them were paid out-of-pocket or covered by commercial insurance. Another limitation is the 
constrained power of survival analysis due to limited length of available data. Since we only had 
access to three years data, the identification of the first nonfatal overdose could be inaccurate, 
and the length of follow up (12 months) may be too short to capture the whole length of time 
staying in the treatment for some MOUD recipients, and to have a sufficient number of events 
(death) to reach a decent statistical power. However, the survival approach was able to justify the 
censored data and reduce bias. The methodology is sound and we will be able to reproduce the 
study with more years’ data available. Lastly, the Medicaid data used in this study had excluded 
dual-eligible population in Medicare. Notwithstanding, this part only accounts for about 20% of 
overall Medicaid beneficiaries. 
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2.1 Abstract 
Objective 
To describe and analyze the involvement of fentanyl and fentanyl analogs (FAs) in drug-related 
deaths in West Virginia (WV), United States. 
Methods 
Retrospective analyses of all WV drug-related deaths from 2005 to 2017 were performed, 
including comparisons of demographic and toxicological characteristics among total deaths, 
deaths in which fentanyl/FAs were present, deaths in which they were absent, heroin-related 
deaths, and prescription opioid-related deaths. 
Results 
Most of the 8813 drug-related deaths were overdoses, with about 11% resulting from 
transportation/ other injuries in which drugs were contributors. Prescription opioid presence 
(without fentanyl) decreased by 75% from 2005–14 to 2015–17 (3545 deaths to 859 deaths, 
respectively), while fentanyl involvement in the deaths increased by 122% between these periods 
(487 to 1082 deaths). Ten FAs were identified (427 instances) after 2015. Alprazolam and 
ethanol were among the top five most frequently identified substances across years. Fentanyl, 
heroin and cocaine replaced oxycodone, diazepam and hydrocodone in the top five beginning in 
2015. Few decedents had a prescription for fentanyl after 2015, with fewer prescriptions also 
present for other controlled substances identified. 
Conclusions 
Fentanyl, rapidly emerging FAs, and other illicit drugs in recent years pose a serious health 
threat even though prescription opioid-related deaths decreased over the same time period. 
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2.2 Introduction 
Opioid-related deaths continue to increase in the United States, resulting in a substantial public 
health burden of about five years of life lost per 1000 population (Gomes et al., 2018)1. Fentanyl 
and fentanyl analog (FA)-related deaths have increased dramatically with much of the fentanyl 
identified consisting of illicitly manufactured fentanyl (IMF) (Armenian et al., 2017; Suzuki and 
El-Haddad, 2017; Centers for Disease Control and Prevention CDC, 2018)2-5. Greater difficulty 
obtaining prescription opioids along with ready heroin availability may have contributed to 
increased IMF use (Hempstead and Yildirim, 2014)6.Potent FAs such as carfentanil (veterinary 
drug) and furanyl fentanyl maintain fentanyl’s pharmacologic effects while being difficult to 
detect with standard toxicological testing (Armenian et al., 2017; Suzuki and El-Haddad, 
2017)2,3. Since fentanyl is about 50–100 times and carfentanil approximately 10,000 times more 
potent than morphine, they and other illicit FAs pose serious health threats (Armenian et al., 
2017; Suzuki and El-Haddad, 2017)2,3. 
Fentanyl/FAs have been found in adulterated prescription drugs and in heroin, cocaine, and 
methamphetamine (Arens et al., 2016; Mars et al., 2017; McCall Jones et al., 2017; CDC, 
2018)4,7-9, resulting in deaths of individuals misusing or abusing these substances (Frank and 
Pollack, 2017)10. Combining IMF/FAs with other opioids increases the overdose danger by 
potentiating respiratory and central nervous system depression, often resulting in rapidly 
occurring death (Fox et al., 2018; Slavova et al., 2017)11,12. 
West Virginia (WV), which is predominantly rural, has the highest per capita drug overdose 
mortality in the United States (Hedegaardet al., 2017)13. Although heroin and synthetic opioids 
such as fentanyl contribute to an increasing number of drug-related deaths nationally (Rudd, 
2016)14, studies have suggested that fentanyl overdoses might be more common in urban and 
27 
 
suburban areas (Marshall et al., 2017)15. The objective of this study was to compare fentanyl and 
FA-related deaths to drug-related deaths not involving fentanyl/FAs in West Virginia. 
2.3 Methods 
A forensic drug database (FDD) was created in 2005 in collaboration with the West Virginia 
Office of the Chief Medical Examiner (WVOCME) to compile data from all WV drug-related 
deaths. West Virginia uses a centralized medical examiner system and the WVOCME maintains 
files for WV deaths. Drug-related death data are available from 2005 through 2017 (a total of 78 
[7%] of 2017 deaths were not available for entry at time of this manuscript). Each FDD case 
includes demographic information (e.g., age, sex, race, weight, height, date of death, zip code of 
residence), cause and manner of death, toxicology findings (e.g., drugs identified, concentrations, 
postmortem interval),whether a prescription was present within the past 30 days for controlled 
substances, autopsy findings, and medical history. Sources used by the OCME data entry 
personnel to compile the FDD data included the death certificate, autopsy report, external 
examination, investigator reports, medical records, police reports, toxicology reports, the West 
Virginia Controlled Substances Monitoring Program (WV CSMP), and any other relevant 
information in the decedent’s file. Medical history information was obtained using a variety of 
sources, including county MEs, scene investigations, prescription records, autopsy reports, and 
medical records when available.  
Deaths were defined as fentanyl or FA-related if one or more of these substances was found 
during postmortem toxicology testing and identified as a cause of or contributor to death in Parts 
I or II of the death certificate. Deaths included those in which overdose was the immediate cause 
of death, or a transportation-related or other injury(e.g., motor vehicle, ATV, drowning, etc.) was 
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the immediate cause of death but drugs were believed to be significant contributors to death(e.g., 
fentanyl and heroin present during confirmatory toxicology in vehicle operator’s death).  
Drug screening is routinely performed on all deaths investigated by the WV OCME, with 
confirmative toxicology tests conducted for most positive screens. Blood and/or tissue samples 
are screened for volatile compounds using gas chromatography with flame ionization detection 
and drugs of abuse using automated enzyme immunoassays. This latter test includes the 
following drugs/drug classes: amphetamines, barbiturates, benzodiazepines, buprenorphine, 
cocaine, fentanyl/fentanyl analogs, methadone, opiates (morphine, codeine, hydrocodone, 
hydromorphone, oxycodone, oxymorphone), and marijuana. In addition to the opiate 
immunoassay, a second immunoassay is specifically used to detect oxycodone and 
oxymorphone. Drugs or drug classes, including many therapeutic and nonprescription drugs, 
which screen positive undergo confirmation testing and quantitation. Fentanyl analogs were 
tested beginning in 2013 to coincide with national reports. Heroin was considered to have been 
used when the drug or its metabolite 6-monoacetylmorphine (6-MAM) was identified in any 
sample tested. Frequently 6-MAM is detectable in vitreous fluid or urine when no longer 
detectable in blood. The femoral or subclavian blood concentration ratio of morphine to codeine 
was also considered when heroin involvement in the death was suspected (Harruff et al., 2015)16. 
Ina small number of cases, heroin was listed on the death certificate as a cause of or contributor 
to death on the basis of a compelling death scene investigation with toxicology reports 
identifying morphine (metabolite of 6-MAM) and small amounts to undetectable codeine. 
Descriptive analyses were used to characterize the drug-related deaths. T-tests and Chi-square 
tests were used for continuous and categorical data comparisons, respectively. Co-intoxicants in 
fentanyl and FA-related deaths were compared between the 2005–2014 and the2015–2017 time 
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periods because the number of fentanyl and FA-related deaths did not increase substantially until 
2015. The number of drugs with a valid prescription (defined as a prescription present within 
30days prior to death) was determined through use of the WV CSMP. Comorbidities identified 
through autopsy reports and other information in decedents files were defined as follows: 
cardiovascular (cardiomyopathy, cardiomegaly, hypertrophy, hypertensive cardiovascular 
disease, ischemic heart disease, atherosclerotic coronary artery disease, cardiac disease, heart 
failure, myocardial infarction), psychiatric other than substance abuse disorder (Alzheimer's 
disease, anxiety disorder, attention deficit hyperactivity disorder, bipolar affective disorder, 
chronic fatigue, delusional disorder, dementia, depression, mania, mental/behavioral disorders, 
obsessive-compulsive disorder, panic attacks, posttraumatic stress disorder, psychosis, 
schizophrenia, suicide attempts/ideation, self-mutilation behavior), pulmonary (asthma, sleep 
apnea, chronic obstructive pulmonary disease, pneumoconiosis), hepatic(hepatitis, cirrhosis, 
alcoholic/other liver disease, hepatic necrosis, hepatic failure), pain (ankylosing spondylitis, 
migraine/headache syndromes, arthritis/polyarthritis/rheumatoid arthritis/osteoarthritis, systemic 
lupus, systemic sclerosis, neuropathy pain, acute pain, chronic pain, fibromyalgia, pancreatitis, 
systemic lupus, hip fracture), and history of substance abuse (drug, alcohol or other substance). 
All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).A P value of less than 
0.05 was considered statistically significant. 
2.4 Results 
A total of 8813WV drug-related deaths from 2005 to 2017 were analyzed. Five data sources 
were reviewed on average per death, with toxicology, investigation and autopsy reports, and 
death certificates used most frequently. Of the 5924 drug-related deaths from 2005 to 2014, 
fentanyl was identified in 487 deaths (8.2%), most of which involved co-intoxicants with only 
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one FA found (Table 1). Of the 2889 drug-related deaths from 2015 to 2017, 1082 (37.5%) 
involved fentanyl and/or FAs. The mean decedent age in fentanyl and/or FA-related deaths was 
significantly lower (seven years) compared to deaths involving prescription opioids. Overall, 
most decedents were male, with about 87% of deaths classified by the OCME as unintentional. 
Body mass index (BMI) did not differ between fentanyl/FA-related and prescription opioid 
deaths from 2005 to 2014, although BMI was slightly but statistically significantly lower 
compared to prescription opioid deaths during 2015–2017. Drug overdose was the primary cause 
of death across years and was significantly higher in the fentanyl/FA-related cases (99%) 
compared to prescription opioid or total drug deaths. A transportation-related accident or other 
injury (e.g., impaired/intoxicated individual hit by vehicle or falling) was the primary cause of 
death in approximately 11%, with one or more drugs considered contributors.  
Multiple drug use was common (77.5%) among drug-related deaths (Table 1). A slight but 
statistically significantly greater number of co-intoxicants was identified in prescription opioid-
related deaths during 2015–2017 (mean=3.2) compared to fentanyl/FA-related deaths 
(mean=2.9). Females tended to have only a slightly higher average number of co-intoxicants 
present than males. Involvement of fentanyl/ FAs in the deaths increased dramatically during 
2015–2017 (Fig. 1) while prescription opioid-related deaths, still a considerable problem, 
decreased (Table 1). From 2012 to 2017, the largest increases in the drugs identified were: 
fentanyl (1325%), methamphetamine (1375%), heroin (279%), and cocaine (171%), with most 
increases occurring from 2015 to 2017. Prescription opioids (not including fentanyl) were 
present in about 30% of 2015–2017 deaths compared to almost 60% of 2005–2014 deaths. Only 
age, manner of death, and cause of death were statistically significantly different between 
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fentanyl/FA-related deaths and prescription opioid deaths from 2005 to 2014, with all 
characteristics compared significantly different during 2015–2017 (Table 1).  
Alprazolam, oxycodone, ethanol, diazepam, and hydrocodone comprised the top five identified 
substances in unintentional deaths from 2005 to 2014, while fentanyl, heroin, ethanol, 
alprazolam, and cocaine were the most common substances in 2015–2017 (Table 2). During 
2015–2017, the most frequent co-intoxicants found together with fentanyl/FAs were heroin 
(36.3%), cocaine (19.9%), alprazolam (15.5%), ethanol (15.1%), and methamphetamine 
(14.7%). Only methamphetamine was found with similar frequency regardless of whether 
fentanyl/FAs were present or absent (p= 0.6430). Of the 1196 unintentional heroin-related deaths 
from 2005 to 2017, 6-MAM was identified in 1061 cases (88.7%) and morphine was present in 
all remaining cases (n = 135). A morphine/codeine concentration ratio in femoral or subclavian 
blood could be calculated in 29 (21.5%) of these latter deaths; the ratio was greater than 1 in all 
cases and greater than 3 in 28 of the 29 cases (96.6%). Scene investigations also helped 
determine the likelihood of heroin involvement in these deaths.  
Since 2015, fentanyl/FA deaths outpaced those of other prescription opioids identified in 
unintentional deaths. The number of fentanyl/FA related deaths exceeded those from other 
substances since 2016 and rose dramatically in 2017 (Fig. 1). Methamphetamine involvement 
has also rapidly increased from 2015 (7.6%) to 2017 (22.6%). Ethanol continues to maintain a 
significant presence in drug-related deaths each year (19.8% in 2017). Benzodiazepines were 
commonly found across years but decreased in 2017.  
Ten different FAs were identified in any death from 2015 to 2017 (427 instances) (Table 3), with 
a single FA identified prior to 2015. The FAs identified include (in decreasing frequency): 
carfentanil, furanyl fentanyl, para-fluoro(iso)butyryl fentanyl, acetyl fentanyl, acryl fentanyl, 
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cyclopropyl fentanyl, butyryl fentanyl, 3-methyl fentanyl, methoxyacetyl fentanyl, and 
tetrahydrofuran fentanyl. They were often identified with co-intoxicant fentanyl, heroin, 
benzodiazepines, cocaine or other FAs. Fentanyl was a co-intoxicant in about 31–35% of deaths 
involving carfentanil and furanyl fentanyl, 87.5% of deaths involving acetyl fentanyl, and 61.3% 
of deaths involving para-fluoro(iso)butyryl fentanyl. Among a total of 317 cases with at least one 
FA present, heroin and benzodiazepines were identified in 121 (38.2%) and 87 (27.4%), 
respectively, with other prescription opioids less commonly found (81 cases; 25.6%).  
The percentage of controlled substances for which decedents had a prescription decreased overall 
from 2005 to 2014 to 2015–2017, but the percentage steadily increased by age, from 9.8% of 
decedents aged 18–24 years to 42% of those 65 years and older. Fewer decedents had a 
prescription for hydrocodone (51.4% vs. 38.8%), oxycodone (39.3% vs. 37.3%), morphine 
(19.9% vs. 9.7%), alprazolam (44.5% vs. 34.5%), and diazepam (28.9% vs. 22.6%) during 2015–
2017 compared to the earlier period. Very few decedents had a prescription for 
methamphetamine. For deaths involving methadone, commonly used in medication- assisted 
treatment for opioid abuse, a prescription was found with slightly higher frequency during 2015–
2017 compared to earlier years (31.2% to 24.2%, respectively), although the number of 
methadone related deaths was much lower recently. Most notable was the recent decline in the 
percentage of decedents who had a prescription for identified fentanyl (23.9% to 1.7%).  
Medical records were accessed for 25.6% (2259/8813) of all deaths (Table 4). Of these, a history 
of substance abuse (drugs and/or alcohol) was significantly higher in unintentional deaths 
involving fentanyl/FAs compared to deaths in which they were absent (87.6% vs. 67.8%), while 
co-morbid cardiovascular (41.1% vs. 50.3%) and pulmonary diseases (17.0% vs. 25.5%) were 
significantly less common in fentanyl/ FA-related deaths. There were no significant differences 
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in co-morbid psychiatric, pain, or hepatic conditions between deaths with or without 
fentanyl/FAs, with percentages in all groups relatively low (less than 20%). 
2.5 Discussion 
Drug-related deaths continue to rise in the United States (Armenian et al., 2017; Frank and 
Pollack, 2017; O’Donnell et al., 2017; Suzuki and El-Haddad, 2017; CDC, 2018)3,4,10,17,18. 
Fentanyl-related WV deaths have continued unabated since 2015, with a steep recent increase. 
Drug involvement in the deaths has also changed, from predominantly prescription opioids to 
illicit drugs, generally with co-intoxicants. This recent shift from predominantly prescription 
opioids to illicit drugs suggests that programs to reduce prescription opioid deaths, e.g., 
prescription drug monitoring programs (PDMPs), are decreasing fatal intoxications from such 
opioids. However, when prescription opioids are less readily available, drug users often switch to 
cheaper, illicit substitutes (Alexander et al., 2016; Fink et al., 2018; Nam et al., 2017; Pergolizzi 
et al., 2018; Seth et al., 2018; Slavova et al., 2017)12,19-23. Our finding of fewer decedents with 
prescriptions for identified controlled substances is consistent with these reports. Although a 
recent review found that PDMPs appeared to reduce overdose deaths, albeit based on low-
strength evidence (Compton and Wargo, 2018)24, they have continued to increase in WV. This 
increase might also be explained in part by geographical isolation, poverty, limited medical 
resources, heavy economic burdens, and social obstacles that could exacerbate the fentanyl 
problem in rural areas (Jozaghi and Marsh, 2017)25.  
Similar to other reports (Hayashi et al., 2018)26, the mean decedent age was significantly 
younger in fentanyl/FA-related deaths compared to other drugs or those involving prescription 
opioids. Compared to non-fentanyl prescription opioids, fentanyl/FA-related deaths in 2015–
2017 ha d a significantly greater proportion of males, lower BMI, and were more likely to be 
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unintentional in nature. Thus, it is important that efforts to reduce fentanyl abuse encompass the 
younger male population.  
Characterizing the co-intoxicants involved in fentanyl-related deaths is important. Fentanyl or a 
FA was present as a single drug in a minority of deaths (12.9%), although to a significantly 
greater extent than single drug prescription opioids (9% of deaths). Co-intoxicants identified 
prior to 2015 were predominantly benzodiazepines and prescription opioids; more recently, they 
were likely to be illicit although benzodiazepine involvement continues to be high. Heroin, 
cocaine, and methamphetamine were present in 36.3%, 19.9%, and 14.7% of all unintentional 
fentanyl/FA-related deaths during 2015–2017, respectively, consistent with reports describing 
regular heroin and cocaine use as risks for fentanyl overdose (Baldwin et al., 2018; Hayashi et 
al., 2018; Mars et al., 2017; McCall Jones et al., 2017; Rubin, 2017)9,26-29. Crystal 
methamphetamine use has been significantly associated with fentanyl identification (Amlani et 
al., 2015; Baldwin et al., 2018; Hayashi et al., 2018)26,27,30, with fentanyl/FAs found to an 
increasing extent in confiscated methamphetamine (CDC, 2018)4. Methamphetamine was 
present to a similar extent in WV fentanyl/FAs present or absent deaths.  
Fentanyl-related deaths with multiple co-intoxicants might partly result from the use of fentanyl-
laced or counterfeit heroin, cocaine, opioids and benzodiazepines (CDC, 2016a; Marinetti and 
Ehlers, 2014; Unick and Ciccarone, 2017; CDC, 2018)4,31-33. This could help explain the rapid 
rise in fentanyl-related deaths in WV, a state with traditionally high prescription opioid deaths. A 
prescription was present in a very small percentage of our recent fentanyl deaths, indicating 
predominantly IMF use or diversion.  
Heroin was identified in over a third of fentanyl/FA-related deaths during 2015–2017 but can be 
difficult to detect due to its very rapid metabolism to 6-monoacetylmorphine, which has a 
35 
 
slightly longer but still relatively short half-life (Harruff et al., 2015)16. Thus, the morphine/ 
codeine concentration ratio can assist in identifying heroin involvement in deaths. Codeine in 
small concentrations is often present in illicit heroin batches. A morphine/codeine ratio greater 
than three likely indicates that heroin use was the source of codeine present, while a ratio smaller 
than one typically indicates codeine ingestion (Harruff et al., 2015)16. In cases where 6-MAM 
was present in our study, all had a ratio greater than one, with most having a morphine/codeine 
ratio above three. Similar results were found in suspected heroin deaths in which 6- MAM was 
absent and a morphine/codeine ratio could be determined. Thus, only a relatively small number 
of 6-MAM-negative deaths might be falsely attributed to heroin, although some cases with 
heroin involvement could be missed.  
The rapid increase in FA deaths represents an unprecedented public health threat (CDC, 2018)5, 
with prescription opioids and benzodiazepines still contributing to a significant number of 
deaths. Although relatively new to WV, FAs were identified for several years in other areas of 
the country (Hibbs et al., 1991)34. A total of ten different FAs were identified in WV deaths 
during 2015–2017, usually with co-intoxicant fentanyl, heroin, benzodiazepines, cocaine or other 
FAs. Carfentanil and furanyl fentanyl were present most often, but new FAs continue to be 
identified.  
Additional trends from the more recent drug-related deaths deserve special mention. Recent 
increases in methamphetamine involvement is of particular concern, particularly with the 
prevalence of cardiovascular disease in WV (CDC, 2016b)31. Heroin and cocaine were 
infrequently involved in WV deaths in past years but now constitute serious health threats. 
Alcohol should not be overlooked since it has consistently been among the top substances 
identified in WV drug-related deaths, present in almost a quarter of such deaths.  
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About 89% of WV drug deaths represented overdoses. Deaths were also included in which a 
transportation-related accident or other injury was the immediate cause of death, but drugs and/or 
alcohol were contributors. While not classified as overdoses, these deaths might have been 
avoided if the person was unimpaired. A total of 953 deaths between 2005 and 2017 fell into 
transportation or other injury categories (e.g., falling, drowning, choking/suffocating, being hit 
by trains or cars, ATV or other vehicular accidents) influenced by the presence of one or more 
substances. Of 321 such deaths from 2015 to 2017, fentanyl was found in 10 (3%) and 
prescription opioids were contributors in 70 (22%) (Table 1). By preventing overdose deaths, 
substance-related injury deaths might also be reduced. Further studies should explore trauma-
related deaths directly or indirectly attributed to impairment.  
Most study decedents had a history of drug and/or alcohol abuse, a known risk factor for opioid-
related mortality (Webster, 2017)35. This history was significantly more common in fentanyl/FA 
associated deaths, consistent with the illicit nature of FAs and the very low percentage of 
prescriptions present for fentanyl in the recent deaths. However, significantly lower rates of co-
morbid cardiovascular and pulmonary conditions, also reported as risk factors for opioid-related 
death (Webster, 2017)35, were found in WV decedents with fentanyl/FAs present. Existing 
diagnoses of psychiatric conditions and pain, reported to be risk factors for opioid mortality 
(Webster, 2017)35, were found in about 20% and 11%, respectively, of our decedents’ files. 
Since comprehensive medical histories were not available in most cases, these figures are likely 
incomplete. Further studies involving direct linkages with medical records are needed to examine 
the association of underlying medical conditions with drug mortality risk.  
Most drug-related death reports have focused on overdoses based on ICD-10 codes (O’Donnell 
et al., 2017; Unick and Ciccarone, 2017)18,33. A particular strength of this study is the use of 
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multiple data sources, including death certificates, autopsy reports, CSMP information, and 
toxicology analyses that allow individual opioids and drug combinations involved to be 
identified. A centralized medical examiner system in WV enables fairly complete decedent data 
to be compiled.  
This study also has potential limitations. Accurately determining intent for manner of death (i.e., 
unintentional vs. suicide) is difficult postmortem. The WV OCME certifies deaths with the 
understanding that the potential for under-reporting suicides is substantial, and the number of 
suicides related to drug overdose deaths are likely underestimated (Rockett et al., 2018)36. 
Relevant data might be missing or incorrectly entered in the case file or FDD. However, data 
were checked for inconsistencies or missing values, with follow-up to the extent possible. Heroin 
can be difficult to identify in decedents due to rapid metabolism, so heroin in some cases might 
be missed. When fentanyl was found as a co-intoxicant, it cannot be determined whether the 
decedent used fentanyl in addition to heroin/other drugs or if heroin/ other drugs were taken that 
unknowingly contained fentanyl. Due to the frequency in which new FAs are appearing in the 
deaths, it is possible that as yet unknown analogs were not detected. A small number of drug-
related deaths from 2017 were not yet entered into the FDD at the time of this study. However, 
preliminary review of these cases found that 31 (39.7%) had fentanyl present. Finally, West 
Virginia is a rural state with a high per capita drug overdose death rate. Although these findings 
might not be representative of other geographic areas, they are consistent with reports of 
increasing FA deaths in several states (CDC, 2018)5.  
The substances involved in drug-related deaths must be closely monitored to ensure that 
appropriate harm reduction strategies are used. The frequency at which new FAs and IMF are 
appearing is particularly concerning since controlled substances monitoring programs cannot 
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track these substances. Routine toxicological detection of FAs is difficult, and clandestine 
laboratories can easily modify fentanyl and its derivatives. Expanded access to addiction 
treatment and ready availability of naloxone to treat acute opioid overdoses are needed (Frank 
and Pollack, 2017; Klebacher et al., 2017; Samet and Kertesz, 2018; Thomson et al., 2017; CDC, 
2018)5,10,37-39. Multifaceted fentanyl outbreak identification, prevention, harm reduction, and 
expanded treatment strategies that consider social, economic, and other contributing factors are 
needed to address the opioid and illicit drug crisis (Dasgupta et al., 2018; CDC, 2018)5,40. 
Education and training of health providers, public health professionals, and health professions 
students are necessary to implement such strategies (Frank and Pollack, 2017; Samet and 
Kertesz, 2018; Thomson et al., 2017)10,38,39. Public health, law enforcement, and other 
government agencies must work in collaboration to halt the production and supply of IMF, FAs 
and other illicit drugs. 
2.6 Conclusions 
Fentanyl involvement increased substantially over time in WV drug related deaths from 2005 to 
2017, with ten different FAs identified since 2015. Prescription opioid presence decreased by 
about half with fentanyl, heroin, ethanol, alprazolam and cocaine constituting the top five 
identified drugs in these deaths since 2015. Alprazolam and ethanol were consistently among the 
top five drugs identified since 2005, with methamphetamine involvement increasing. In contrast, 
the presence of a prescription for most controlled substances identified in the deaths has been 
decreasing. Deaths involving fentanyl and newly identified FAs could represent the “tip of the 
iceberg” since fentanyl derivatives are often not readily detected. 
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Table 1 Changes in fentanyl, fentanyl analog, heroin, and non-fentanyl prescription opioid-related deaths in West Virginia, 2005-2017 (n = 8813). 
  2005 - 2014 2015 - 2017 
Characteristics 
Total 
Drug-
Related 
Deathsa 
n (%) 
Fentanyl 
and/or 
Analogsb 
n (%)  
Heroinc 
n (%) 
Prescription 
Opioid(s)d 
n (%) 
p - 
valuee 
Total 
Drug-
Related 
Deathsa 
n (%) 
Fentanyl 
and/or 
Analogs 
n (%)  
Heroinc 
n (%) 
Prescription 
Opioids(s)d 
n (%) 
p - 
valuee 
Totalf  5924 (NA) 487 (8.2) 508 (8.6) 3545 (59.8) NA 
2889 
(NA) 
1082 
(37.5) 
290 
(10.0) 
857 (29.7) NA 
Age (mean, SD) 
41.6 (11.8) 39.7 (11.3) 
36.1 
(10.7) 
41.3 (11.4) 0.0039 
42.1 
(12.3) 
39.2 (11.2) 
38.2 
(11.2) 
46.4 (11.4) <0.0001 
Male 3921 
(66.2) 
313 (64.3) 
402 
(79.1) 
2240 (63.2) 0.6386 
1952 
(67.6) 
766 (70.8) 
202 
(69.7) 
515 (60.1) <0.0001 
BMI (mean, SD) 
28.9 (7.6) 29.2 (6.9) 
28.4 
(6.6) 
29.6 (7.9) 0.2544 
28.4 
(7.8) 
28.1 (7.0) 
28.9 
(7.7) 
29.3 (8.4) 0.0010 
Number of drugs 
present 
    
  
     
Single drug 
1320 
(22.3)   
48 (9.9) 97 (19.1) 366 (10.3) 
0.8711 
664 
(23.0) 
140 (12.9) 59 (20.3) 74 (8.6) 
0.0018 
2 drugs 
1539 
(26.0) 
126 (25.9) 
164 
(32.3) 
967 (27.3) 
833 
(28.8) 
309 (28.6) 
123 
(42.4) 
235 (27.4) 
3 drugs 
1354 
(22.9) 
138 (28.3) 
129 
(25.4) 
941 (26.6) 
659 
(22.8) 
302 (27.9) 63 (21.7) 237 (27.7) 
4 drugs 895 (15.1) 97 (19.9) 66 (13.0) 651 (18.4) 
409 
(14.2) 
202 (18.7) 24 (8.3) 161 (18.8) 
5 or more drugs 816 (13.8) 78 (16.0) 52 (10.2) 620 (17.5) 
324 
(11.2) 
129 (11.9) 21 (7.2) 150 (17.5) 
Number of drugs 
present by sex 
(mean, SD) 
          
Female 3.2 (1.7) 3.3 (1.6) 3.1 (1.7) 3.5 (1.7) 0.2543 3.0 (1.6) 3.1 (1.4) 2.6 (1.5) 3.5 (1.7) 0.0013 
Male 2.6 (1.4) 3.1 (1.3) 2.6 (1.4) 3.0 (1.4) 0.3451 2.5 (1.4) 2.9 (1.3) 2.4 (1.1) 3.0 (1.5) 0.0246 
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Total  2.8 (1.6) 3.2 (1.5) 2.7 (1.4) 3.2 (1.5) 0.8893 2.7 (1.5) 2.9 (1.3) 2.4 (1.3) 3.2 (1.6) <0.0001 
Manner of death 
 
    
     
Unintentional 
4982 
(84.1) 
455 (93.4) 
499 
(98.2) 
3141 (88.6) 
0.0015 
2670 
(92.4) 
1068 
(98.7) 
284 
(97.9) 
762 (88.9) 
<0.0001 
Suicide 517 (8.7) 8 (1.6) 8 (1.6) 175 (4.9) 118 (4.1) 8 (0.7) 0 (0.0) 44 (5.1) 
Other (Could not 
be determined, 
homicide) 
425 (7.2) 24 (4.9) 1 (0.2) 229 (6.5) 101 (3.5) 6 (0.6) 6 (2.1) 51 (6.0) 
Cause of death by 
category 
     
 
    
Overdose 
5292 
(89.3) 
480 (98.6) 
506 
(99.6) 
3401 (95.9) 
0.0165 
2568 
(88.9） 
1072 
(99.1) 
284 
(97.9) 
787 (91.8) 
<0.0001 
Transportation 
(occupant, 
pedestrian, etc.) 
197 (3.3) 2 (0.4) 1 (0.2) 40 (1.1) 223 (7.7) 5 (0.5) 4 (1.4) 50 (5.8) 
Other injuries 
(fall, firearm, 
drowning, etc.) 
435 (7.3) 5 (1.0) 1 (0.2) 104 (2.9) 98 (3.4) 5 (0.5) 2 (0.7) 20 (2.3) 
NA: not applicable. 
  a  Includes deaths involving any drug or alcohol. 
  b 2005-2014 included only 1 fentanyl analog identified in 1 death. 
  c Any death involving heroin with no fentanyl and/or analogs. 
  d Any death involving buprenorphine, codeine, hydrocodone, hydromorphone, methadone,  morphine,  oxycodone, oxymorphone, diphenoxylate, 
propoxyphene, meperidine or tramadol; no fentanyl and/or analogs or heroin. 
  e Comparison between fentanyl and/or analogs and prescription opioid(s). 
   f Total drug-related deaths during time period. 
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Table 2 
Drugs most frequently present in total, 2005-2014, and in total and fentanyl ± fentanyl analog-related unintentional deaths in West Virginia, 2015-
2017 (n = 7652). 
2005-2014 (n = 4982) 2015-2017 (n = 2670) 
Substance 
Totala   
n (%) Substance 
Totala   
n (%) 
F ± FA Present  (n = 
1068) 
n (%) 
F ± FA 
Absent (n 
= 1602) 
n (%) p - valueb 
Alprazolam 1551 (31.1) Fentanyl 899 (33.7) NA NA NA 
Oxycodone 1430 (28.7) Heroin 672 (25.2) 388 (36.3) 284 (17.7) <0.0001 
Ethanol 1262 (25.3) Ethanol 593 (22.2) 161 (15.1) 432 (27.0) <0.0001 
Diazepam 1244 (25.0) Alprazolam 495 (18.5) 166 (15.5) 329 (20.5) 0.0011 
Hydrocodone 1029 (20.7) Cocaine 457 (17.1) 213 (19.9) 244 (15.2) 0.0015 
Methadone 783 (15.7) Oxycodone 429 (16.1) 95 (8.9) 334 (20.8) <0.0001 
Cocaine 730 (14.7) Methamphetamine 403 (15.1) 157 (14.7) 246 (15.4) 0.6430 
Heroin 524 (10.5) Diazepam 368 (13.8) 116 (10.9) 252 (15.7) 0.0003 
Morphine 520 (10.4) Hydrocodone 273 (10.2) 60 (5.6) 213 (13.3) <0.0001 
Fentanyl 454 (9.1) Gabapentin 248 (9.3) 30 (2.8) 218 (13.6) <0.0001 
Oxymorphone 402 (8.1) Clonazepam 217 (8.1) 63 (5.9) 154 (9.6) 0.0006 
Clonazepam 358 (7.2) Morphine 207 (7.8) 114 (10.7) 93 (5.8) <0.0001 
Citalopram 301 (6.0) Buprenorphine 189 (7.1) 46 (4.3) 143 (8.9) <0.0001 
Diphenhydramine 299 (6.0) Oxymorphone 145 (5.4) 20 (1.9) 125 (7.8) <0.0001 
Tramadol 214 (4.3) Methadone 95 (3.6) 22 (2.1) 73 (4.6) 0.0006 
NA: not applicable; F: fentanyl; FA: fentanyl analogs. 
  a Total drug-related unintentional deaths during time period (excludes cases with other manners of death). 
  b Comparison between deaths in which F and/or FA were present or absent. 
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Table 3 Fentanyl analogs idenified in drug-related deaths in West Virginia, 2015 - 2017 (n = 2889). 
Characteristi
c 
Carfent
anil 
n (%) 
Furanyl fentanyl 
n (%) 
Para-
fluoro(iso)b
utyryl 
fentanyl 
n (%) 
Acetyl 
fentanyl 
n (%) 
Acryl 
fentan
yl 
n (%) 
Cyclopropy
l fentanyl 
n (%) 
Butyryl 
fentanyl 
n (%) 
3-
Methyl 
fentany
l 
n (%) 
Methoxya
cetyl 
fentanyl 
n (%) 
Tetrahydro
furan 
fentanyl 
n (%) 
Total No. of 
cases 
117 104 75 56 29 20 10 8 7 1 
First 
identified 
date 
2016/A
ug 
2015/Jan 2015/Jan 2013/Jan 
2015/J
an 
2017/Jun 
2016/Dec 
2016/Se
pt 
2017/Sept 2017/April 
Age (mean, 
SD) 
38.8 
(11.7) 
40.1 (11.2) 40.9 (11.3) 37.4 (9.7) 
35.0 
(9.2) 
39.6 (11.6) 44.1 (8.6) 
33.6 
(10.2) 
43.4 (14.2) 26.0 (.) 
Male 
75 
(64.1) 
69 (66.3) 60 (80.0) 35 (62.5) 
20 
(69.0) 
17 (85.0) 10 (100.0) 6 (75.0) 5 (71.4) 0 (.) 
Number of 
drugs 
present 
(mean, SD) 
3.2 (1.6) 3.9 (1.4) 4.1 (1.3) 3.8 (1.4) 
3.5 
(1.3) 
3.2 (1.6) 4.7 (1.8) 
2.4 
(0.5) 
4.4 (1.9) 4 (.) 
Single 
drug 
16 
(13.7) 
2 (1.9) 1 (1.3) 1 (1.8) 2 (6.9) 4 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
2 drugs 
27 
(23.1) 
14 (13.5) 9 (12.0) 8 (14.3) 
5 
(17.2) 
3 (15.0) 1 (10.0) 5 (62.5) 1 (14.3) 0 (0.0) 
3 drugs 
28 
(23.9) 
26 (25.0) 12 (16.0) 17 (30.4) 
9 
(31.0) 
5 (25.0) 2 (20.0) 3 (37.5) 1 (14.3) 0 (0.0) 
4 drugs 
24 
(20.5) 
32 (30.8) 29 (38.7) 17 (30.4) 
7 
(24.1) 
4 (20.0) 2 (20.0) 0 (0.0) 2 (28.6) 1 (100.0) 
5 or more 
drugs 
22 
(18.8) 
30 (28.8) 24 (32.0) 13 (23.2) 
6 
(20.7) 
4 (20.0) 5 (50.0) 0 (0.0) 3 (42.9) 0 (0.0) 
Cases with 
concurrent 
          
   Fentanyl 
41 
(35.0) 
32 (30.8) 46 (61.3) 49 (87.5) 
14 
(48.3) 
9 (45.0) 6 (60.0) 1 (12.5) 6 (85.7) 0 (0.0) 
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   Other 
fentanyl 
analog(s) 
28 
(23.9) 
31 (29.8) 41 (54.7) 1 (1.8) 
15 
(51.7) 
5 (25.0) 5 (50.0) 2 (25.0) 3 (42.9) 1 (100.0) 
   Other 
prescription 
opioid(s)a 
28 
(23.9) 
25 (24.0) 14 (18.7) 20 (35.7) 
3 
(10.3) 
2 (10.0) 3 (30.0) 2 (25.0) 2 (28.6) 1 (100.0) 
   Heroin 
26 
(22.2) 
48 (46.2) 42 (56.0) 29 (51.8) 
17 
(58.6) 
6 (30.0) 5 (50.0) 1 (12.5) 2 (28.6) 1 (100.0) 
   
Benzodiazepi
ne(s)b 
34 
(29.1) 
39 (37.5) 19 (25.3) 15 (26.8) 
3 
(10.3) 
4 (20.0) 3 (30.0) 0 (0.0) 1 (14.3) 0 (0.0) 
   Ethanol 
13 
(11.1) 
18 (17.3) 9 (12.0) 10 (17.9) 2 (6.9) 0 (0.0) 2 (20.0) 0 (0.0) 1 (14.3) 0 (0.0) 
   
Methamphet
amine 
28 
(23.9) 
13 (12.5) 5 (6.7) 4 (7.1) 
6 
(20.7) 
6 (30.0) 2 (20.0) 1 (12.5) 4 (57.1) 0 (0.0) 
   Cocaine 
19 
(16.2) 
20 (19.2) 22 (29.3) 12 (21.4) 
3 
(10.3) 
6 (30.0) 3 (30.0) 4 (50.0) 2 (28.6) 0 (0.0) 
Most 
frequently 
occuring 
analog co-
intoxicant 
Furanyl 
fentanyl
, 17 
(14.5) 
Para-
fluoro(iso)butyryl
/butyryl fentanyl, 
32 (30.8) 
Furanyl 
fentanyl, 32 
(42.7) 
Furanyl 
fentanyl, 
acryl 
fentanyl, 
para-
fluoro(iso)b
utyryl 
fentanyl, 1 
(1.8) 
Furan
yl 
fentan
yl, 13 
(44.8) 
Para-
fluoro(iso)b
utyryl 
fentanyl,  
Butyryl 
fentanyl, 2 
(10.0) 
Para-
fluoro(iso)b
utyryl 
fentanyl, 5 
(50.0) 
Carfent
anil, 
Furanyl 
fentanyl
, 1 
(12.5) 
Carfentani
l, 2 (28.6) 
Carfentanil, 
1 (100.0) 
  a Any death involving buprenorphine, codeine, hydrocodone, hydromorphone, methadone,  morphine,  oxycodone, oxymorphone, diphenoxylate, 
propoxyphene, meperidine or tramadol; no fentanyl or heroin 
  b Benzodiazepines include alprazolam, clonazepam, chlordiazepoxide, diazepam, lorazepam, oxazepam, temazepam. 
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Table 4  
Comorbid medical conditions in unintentional drug-related deaths (n = 7652) - fentanyl + FAs vs. non-fentanyl + FAs in 
West Virginia, 2005-2017. 
Medical Conditions 
Total Deaths 
n (%) 
Fentanyl and/or Analogs Present 
n (%) 
Fentanyl and/or Analogs 
Absent 
n (%) p - valueb 
Totala 6837 1420 5417 - 
Cardiovascular 3306 (48.4) 584 (41.1) 2722 (50.3) <0.0001 
Psychiatric 1342 (19.6) 299 (21.1) 1043 (19.3) 0.128 
Pulmonary 1622 (23.7) 241 (17.0) 1381 (25.5) <0.0001 
Hepatic 660 (9.7) 142 (10.0) 518 (9.6) 0.6192 
Pain 738 (10.8) 154 (10.9) 584 (10.8) 0.9447 
History of Abuse 4915 (71.9) 1244 (87.6) 3671 (67.8) <0.0001 
  aTotal cases with available medical history data; percentages calculated using total number as denominator.   
  bComparsion between fentanyl and/or analogs present vs. fentanyl and/or analogs absent. 
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Fig. 1. Fentanyl ± fentanyl analogs and other drug involvement in unintentional deaths in West Virginia, 2012- 2017. 
 
 
Solid line with solid square = Fentanyl and/or analogs, dotted line with hollow diamond = Benzodiazepines, solid line with solid 
triangle = Heroin, dotted line with hollow circle = Methamphetamine, solid line with solid diamond = Ethanol, dotted line with 
hollow square = Cocaine, solid line with solid circle = Oxycodone, dotted line with hollow triangle = Hydrocodone. 
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3.1 Abstract 
Objective 
The study aims to examine recurrent opioid overdose and how changes in receipt of Medication 
for Opioid Use Disorder (MOUD) following a non-fatal overdose influence risk of mortality 
among the West Virginia (WV) Medicaid population.  
Methods 
West Virginia Medicaid claims data was obtained from 2014 to 2016. People with an index non-
fatal opioid overdose were identified as the first in the dataset using ICD codes and they were 
then followed up as a cohort for one year.  Occurrence of recurrent opioid overdose and changes 
in receipt of MOUD and other medication use were examined.  
Results 
A total of 399,683 (77.8%) consecutively enrolled WV Medicaid beneficiaries from 2014 to 
2016 were analyzed in the study. A total of 2995 people experienced 3525 documented 
overdoses and 389 (13.0%) of them had multiple overdoses (291 had two overdoses, 68 had 
three overdoses, and 30 had four to seven overdoses), resulting in an average of 1.18 overdoses 
per person in the 12-month follow up. Only 1140 (38.1%) of people were confirmed a diagnosis 
of OUD, and 431(25.3%) received MOUD at any time, of whom 273 (63.3%) received 
buprenorphine hydrochloride and/or Suboxone, 78 (18.1%) received naltrexone, and 80 (18.6%) 
received both medications. There were 125 patients who initiated MOUD after the index 
overdose. The median time staying in MOUD treatment was 88 days. 
Conclusions 
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Only a quarter of people who experienced opioid overdose had received MOUD at any time and 
half of them stayed in the treatment less than 3 months, suggesting limited effectiveness. In 
addition of those overdosing only 38% had a diagnostic code for OUD in their record. Although 
a nonfatal overdose represents an opportunity to initiate MOUD, it was certainly under-utilized 
among WV overdose population. 
3.2 Introduction 
WV leads the nation in drug overdose mortality with the highest mortality rate of 58 per 100,000 
as of 2017, almost 3 times the U.S. average (Wolf et al., 2020; Scholl et al., 2019)1,2. The current 
opioid crisis has strained the capacity of health care and social service resources and taken a 
significant toll on individuals, families, communities, and counties in WV (Saloner et al. 2019)3. 
Medicaid programs have effectively respond to the opioid crisis by expanding treatment 
coverage and reforming treatment delivery systems (Barnes et al., 2020)4. Approximately 29% of 
the WV population are covered by Medicaid, and this makes WV rank highest in the nation in 
terms of proportion of population covered (KFF 2018)5. According to West Virginia Department 
of Health and Human Resources (WVDHHR)6, 71% of  drug overdose decedents were enrolled 
in Medicaid in the 12 months prior to their death as compared to only 23% West Virginia’s adult 
population aged 19-64. Specifically, of those decedents with Medicaid enrollment, 81% had 
medical claims within 12 months prior to their date of death, excluding those decedents who only 
used the benefit within 48 hours before death6. As for emergency department (ED) visits, 68% of 
decedents with Medicaid had at least one ED visit in the 12 months prior to death.  
Expansion of Medicaid started in 2014, and served as an important step in increasing 
accessibility of medications for opioid use disorder (MOUD) for persons with substance abuse 
disorder (WVDHHR 2017; Sharp et al. 2018)5,7. In 2017 the WV DHHR Bureau for Medical 
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Services (BMS) gained approval for a Medicaid Section 1115 waiver to develop a continuum of 
care for individuals with substance use issues starting in January 2018 which expanded the 
services offered for substance abuse treatment. 
The three Food and Drug Administration (FDA) approved MOUD (methadone, buprenorphine, 
and naltrexone) have been shown to be effective treatment options in reducing drug use, 
compulsive drug seeking, substance use relapse, overdose, and lowering mortality (Sharp et al. 
2018; Schwartz et al. 2013; Rudd 2016; Banta-Green et al. 2017; Zoorob 2019; Leshner and 
Mancher 2019)7-12, yet they are infrequently provided to OUD patients (Larochelle et al., 2018; 
Frazier et al., 2017; Larochelle et al., 2016)13-15. Unfortunately, the need for care far exceeds the 
current treatment infrastructure in West Virginia, resulting in long waiting lists, and eventual 
overdoses for many persons actively seeking treatment (Pollini et al. 2006)16. In addition , 
patients are also suffering from many comorbid drug-related mental health conditions, such as 
anxiety, bipolar, depression, alcohol use disorder and other drug use disorders, which increase 
overdose risk (Bohnert et al., 2012; Suffoletto and Aeigler et al., 2020)17,18. 
Moreover, persons experiencing nonfatal overdose are at increased risk of overdose death 
(Coffin et al. 2007)19. This risk is further intensifying in states like West Virginia experiencing 
geographic isolation 20(Hall et al. 2008) and having limited medical resources, resulting in gaps 
between need for sustainable treatment and the state’s capacity to deliver these options 21(Jones 
et al. 2015). Given the fact that potent fentanyl and fentanyl analogs are increasingly involved in 
opioid overdoses, the number of non-fatal overdoses before mortality is decreasing 13,22,23(Frazier 
et al. 2017; Slavova et al. 2017; Massachusetts Department of Public Health, 2017), suggesting 
urgency of starting treatment early to prevent deaths in  OUD patients. Considering the 
substantial burden of the chronic nature of OUD, repeated overdose, and psychiatric 
 54 
 
comorbidities among people who overdose, it is important to understand recurrent opioid 
overdose and changes of receipt of MOUD following a non-fatal overdose. Previous studies 
(Larochelle et al., 2018; Suffoletto and Aeigler et al., 2020)13,18 have shown that survival 
modelling approach could be used to determine whether recurrent opioid overdose was 
associated with increased risk of mortality, and receipt of MOUD was associated with decreased 
risk of mortality. Our study sought to examine recurrent opioid overdoses and how changes in 
receipt of Medication for Opioid Use Disorder (MOUD) following a non-fatal overdose among 
the West Virginia (WV) Medicaid population affect risk of subsequent mortality. 
3.3 Methods  
Sample design 
West Virginia Medicaid claims data was obtained from WV Medicaid. They created a Common 
Data Model (CDM) to incorporate an extensively cleaned subset of WV Medicaid data that was 
designed to study opioid-related measures.  The CDM included WV Medicaid data from 2014 to 
2016 for persons aged 18-64 and excluded about 20% of people who had dual-eligibility with 
Medicare, as Medicare is the primary payer and Medicaid does not include all claims from this 
group. An overdose cohort was then created from CDM by selecting continuously enrolled 
persons ages 18 to 64 with at least one nonfatal overdose event identified by ICD codes 
(Appendix A, ICD-9: 965.00-965.02, 965.09, E850.0-E850.2 or ICD-10: X40-X44, X60-X64, 
X85, Y10-Y14) from emergency department (ED) visits or hospitalization. These ICD-9 codes 
have been validated with 81% positive predictive values for identifying fatal or nonfatal opioid 
overdose occurred before October, 2015 24(Green et al., 2017). Another study suggested that 
ICD-10 codes are able to capture more opioid-related hospitalizations that were otherwise missed 
by ICD-9 codes (Heslin et al., 2017)25. Multiple opioid overdoses that occurred during one 
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hospitalization interval (admission and discharge date) were counted as one overdose event. Two 
overdoses recorded within two days were also accounted as one overdose event. Thus, a 
recurrent overdose event was defined as one occurring at least two days after the previous 
overdose (avoid potential carry-on effect from previous overdose). Among those who had at least 
12 months length of observation overdose free, the first nonfatal overdose identified was marked 
as the index overdose. The retrospective cohort follow-up starts with the index overdose, and 
ends with death or with beneficiaries dropping out within 12 months after the index overdose. 
The cohort excluded those who died within 30 days of index overdose (make sure every subject 
had at least one-month follow up) and patients with any cancer diagnosis (avoid confounding 
effect from cancer) at any time of cohort. The ICD -9 and ICD-10 codes used to identify cancer 
were listed in Appendix A. Missing values were checked for age and gender and no one was 
excluded for this reason.    
This study was reviewed and approved by the Institutional Review Board (protocol number: 
1711862183A001) at the West Virginia University, Morgantown, WV.  
Analysis Plan 
The primary outcome of interests in this aim are recurrent overdose and relationship to receipt of 
MOUD. The receipt of MOUD was identified from both pharmacy datasets using NDC codes 
(Appendix B), and from inpatient and outpatient datasets using procedure code. First, the 
descriptive statistical analysis were performed to describe the opioid overdose cohort. Median 
was reported for continuous variables; number and percentage were reported for categorical 
variables. Demographic characteristics including age, gender, and Medicaid eligibility category 
were analyzed. The number and frequency of overdose events, the monthly receipt of MOUD, 
the number and type of frequently present mental health conditions (including anxiety, bipolar, 
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depression, alcohol use disorder, and substance use disorder) identified using ICD-9 or ICD-10 
codes were also analyzed. Descriptive analyses comprise medication (including opioid 
analgesics and benzodiazepines) use patterns before and after the index overdose. 
3.4 Results 
A total of 513,707 Medicaid beneficiaries aged 18 to 64 were included in the CDM and 399,683 
(77.8%) of them were continuously enrolled over the 3 years from 2014 to 2016 (Figure 1). No 
significant difference of demographic characteristics, including age, gender and race, between 
those continuously enrolled and non-continuously enrolled were identified. There were slight 
difference among eligibility categories among the two groups: young people were more likely to 
drop out of enrollment and non-disabled adults were less likely to drop out.  
Of those continuous enrollees, there were 2,995 people (0.75%) who had experienced at least 
one opioid overdose over the 3-year period. The number of overdoses increased by 45% and 
59% in 2015 and 2016 respectively, compared to the previous year (Table 1). The median period 
was 133 days between the first two overdoses, 74.5 days between the following two overdoses, 
and 69 days between the third and the fourth overdose. 
There were initially 4472 overdoses documented among all 2995 continuously enrolled 
population. However, using 2 days as a cut-off (Olfson et al., 2018)26 to distinguish distinct 
overdoses, 21% (n = 947) of overdose records were removed since they happened on the same 
day or the next day leaving a total of 3525 overdose related claims for the 2,995 individuals who 
had any overdose, of which 2606 (87%) had only 1 overdose and 389 (13%) had multiple 
overdose (number of overdose = 919), resulting in on average 1.18 overdose per person. Among 
people who had multiple overdoses, 291 had two overdoses, 68 had three overdose, 21 had four 
overdoses, and 9 had from five to seven overdoses. Compared with single overdose group, 
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multiple overdoses group shared similar demographic characteristics other than a significantly 
younger age (37.0 vs. 38.5, p = 0.0129) (Table 1). Frequency distribution of comorbid mental 
health conditions were similar, as the single overdose group and multiple overdoses group share 
similar proportion of anxiety diagnosis (10.6% vs. 10.5%), bipolar diagnosis (5.3% vs. 4.7%), 
alcohol use disorder (5.0% vs. 4.0%), other drug use disorder (36.2% vs. 37.7%), but only a 
higher rate of depression diagnosis (14.6% vs. 11.3%, p = 0.0025).  
Additionally, among continuously enrolled beneficiaries who had at least one opioid overdose, 
1140 (38.1%) of them had confirmed diagnosis of OUD. A total of 937 (82.2%) OUD patients 
died and 348 (37.1%) of them died of overdose. The median time interval between the first 
diagnosis of OUD and death is 494 days. Among those who died of overdose, the median time 
interval between the first diagnosis of OUD and death is 528.5 days. Among those who 
experienced an overdose, 272 (23.9%) were diagnosed after the index overdose with a median 
time interval of 119.5 days, 404 (35.4%) were diagnosed on the same date of index overdose, 
and remaining 464 (40.7%) were diagnosed prior to the index overdose with a median time 
interval of 269 days. 
After excluding 1180 subjects with less than 12 months observation time period prior to the 
index overdose, 43 who died within 30 days of index overdose, and 69 with cancer diagnosis, the 
final survival cohort includes 1703 patients with 2001 records of overdoses (1.17 overdose per 
person on average), and 84 (4.9%) of them died within the following 12 months. Only 431 
(25.3%) of patients who overdosed had ever received MOUD, among whom 273 (63.3%) 
received buprenorphine (buprenorphine hydrochloride and/or Suboxone), 78 (18.1%) received 
naltrexone, and 80 (18.6%) received both medications. Specifically, 125 (29%) initiated MOUD 
after the index overdose, 201 (46.6%) had initiated MOUD but dropped out before the index 
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overdose, and the remaining 105 (24.4%) initiated and continued the treatment through the index 
overdose. The median time staying in the MOUD treatment was 88 days, ranging from 2 to 1094 
days. Notably, people who received any MOUD at any time had a higher rate of repeated 
overdose compare with people who never received any MOUD (13.5% vs. 9.8%, p-value = 
0.03). 
As unadjusted analysis of monthly receipt of medication shows (Figure 2) the proportion of 
people receiving opioid analgesics and benzodiazepines decreased from 21-22% by 
approximately 0.31% and 0.37% per month after the index overdose, respectively. Conversely, 
in the 12 months after an index overdose, the proportion of people receiving Suboxone increases 
by 0.19% per month, while the proportion of people receiving buprenorphine hydrochloride and 
naltrexone decreased to 0 and 0.3%, respectively.  
3.5 Discussion   
From 2014 to 2016, the number of overdoses occurred among WV Medicaid population 
increased around 50% for every year with a significant amount of people experiencing recurrent 
overdoses. In addition, the length of interval between two overdoses decreased as the number of 
recurrent overdoses increased, suggesting overdose occurred more frequently. Considering the 
drastically increased number of opioid overdoses every year, the task to curb opioid overdose 
remains challenging as the proportion of people receiving any type of MOUD after an index 
overdose is low. Despite overall observed increasing trend of receipt of MOUD at monthly level, 
still only about 5-10% of people received MOUD, which is far below the rates reported in 
Massachusetts (30% from 2012 to 2014) and Pennsylvania (33% from 2008 to 2013) (Larochelle 
et al., 2018; Frazier et al., 2017)13,14. We may have much less accessibility to treatment. Another 
issue is the high rate of comorbid mental health conditions, especially given that almost a third of 
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the overdose population had other drug use disorders, including stimulants, cannabis related 
disorders (Appendix B). Currently we have MOUD to effectively treat OUD, however, we do 
not have any efficacious medications for stimulant use disorders (Ellis et al., 2018)27. The high 
rates of SUD and OUD associated with high rates of prescription of opioid analgesics and 
benzodiazepines, which were at high risk of abuse and further worsen people’s health.  
The study also observed that people who received any MOUD at any time had a significantly 
higher rate of repeated overdose compared with people who never received any MOUD. The 
reason might be that the discontinuation of MOUD would elevate the risk of opioid overdose 
(Sordo et al., 2017; Davoli et al., 2007)28,29, which deters many people who previously 
experienced overdose from receiving MOUD treatment. Almost 5% of this population died 
within 12 months (excluding cancer patients and those who died within 30 days of index 
overdose), which is close to the MA study (4.7%) (Larochelle et al., 2018)13, and over 10% 
experienced another overdose, resulting in high burden of opioid overdose which urgently 
needed any opportunity to initiate MOUD as soon as possible and keep the patients in the 
treatment long enough to have effective prognosis. Since over half of those deaths occurred 
among people aged 45 years or older, maybe elderly should be considered of high priority of 
referring for treatment. In addition, despite of an overall trend of decreasing prescription of 
opioids and benzodiazepines, there were clear drops after the index overdose. The monthly rate 
of prescription was still close to 20% after 12 month of index overdose. Although it is well 
known that opioid use or benzodiazepine use are risk factors leading to opioid overdose, how 
observed decreased prescription of opioids and benzodiazepines contributes to the next overdose 
or death was unclear among this population (Larochelle et al., 2016; Jones et al., 2015)15,21.  
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Limitations of this study include inability to analyze receipt of methadone since methadone was 
not covered by WV Medicaid until January 1st, 2018, restriction to those continuously enrolled. 
However, few clinics offer methadone treatment in WV and most of them were paid out-of-
pocket or covered by commercial insurance. The Medicaid data used in this study excluded dual-
eligibility population with Medicare, which only accounts for 20% of overall Medicaid data. Due 
to only 1-year follow up, the study failed to capture the whole length of time staying in the 
treatment for some MOUD recipients. The study also did not analyze the effect of 
discontinuation of MOUD on recurrent overdose and mortality.  
Considering the substantial burden of the chronic nature of OUD, repeated overdoses, psychiatric 
comorbidities, and relatively high prescription rates of opioids or benzodiazepines, it is important 
to gain a deeper understanding of the circumstances that influence fatal and nonfatal opioid 
overdoses. A further survival analysis is needed to evaluate MOUD effectiveness among this 
population while controlling for the previously discussed covariates, and expected to provide 
more details on how to curb opioid overdose.  
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Figure 1. Flow chart of case selection of opioid overdose cohort 
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Figure 2. Monthly receipt of opioid analgesic, benzodiazepines and medication for opioid 
use disorder 
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Table 1 Demographic and Medicaid-related Characteristics among Opioid Overdose 
Population (N = 2995) 
 
  Overalla Single Overdoseb Multiple Overdoseb 
Number of people 2995 2606 (87.0%) 389 (13.0%) 
Number of overdose 3525 2606 (73.9) 919 (26.1) 
  2014 743 (21.1)c 547 (73.6) 196 (26.4) 
  2015 1075 (30.5)c 807 (75.1) 268 (24.9) 
  2016 1707 (48.4)c 1252 (73.3) 455 (26.7) 
Number of death 283 (9.5) 238 (84.1) 45 (15.9) 
Age 38.3 ± 11.7 38.5 ± 11.8 37.0 ± 11.6 
  18 - 29 622 (20.8) 619 (84.8) 111 (15.2) 
  30 - 44 1294 (43.2) 1080 (86.4) 170 (13.6) 
  45 - 64 1079 (36.0) 907 (89.4) 108 (10.6) 
Male 1511 (50.5) 1313 (86.9) 198 (13.1) 
Race    
  Non-Hispanic white 2655 (88.7) 2302 (86.7) 353 (13.3) 
  Non-Hispanic black 93 (3.1) 84 (90.3) 9 (9.7) 
  Hispanic 45 (1.5) 36 (80.0) 9 (20.0) 
  Others 202 (6.7) 184 (91.1) 18 (8.9) 
Eligibility categoryd    
  Pregnant Women 43 (1.4) 36 (83.7) 7 (16.3) 
  Children 88 (2.9) 75 (85.2) 13 (14.8) 
  Disabled Adults 152 (5.1) 131 (86.2) 21 (13.8) 
  Non-Disabled Adults 413 (13.8) 358 (86.7) 55 (13.3) 
  Expansion Adults 1251 (41.8) 1092 (87.3) 159 (12.7) 
Psychiatric conditions    
  Anxiety 317 (10.6) 233 (73.5) 84 (26.5) 
  Depression 413 (13.8) 310 (75.1) 103 (24.9) 
  Bipolar 153 (5.1) 111 (72.5) 42 (27.5) 
  Alcohol use disorder 141 (4.7) 105 (74.5) 36 (25.5) 
  Drug use disorder 1109 (37.0) 766 (69.1) 343 (30.9) 
Note: a percentage was calculated by column; 
b percentage was calculated by row. 
c percentage was calculated by the number of overdose. 
d 1048 (35%) had missing eligibility category. 
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4.1 Abstract 
Objective 
The study aims to identify associations between the time of initiation of medication for opioid 
use disorder (MOUD) and risk of mortality for 1 year following a medically treated nonfatal 
overdose among a West Virginia (WV) Medicaid enrollee, adjusting for recurrent overdose and 
other risk factors. 
Methods 
A retrospective cohort including 1703 WV Medicaid beneficiaries ages 18-64 were followed 
after a nonfatal opioid overdose starting January 1, 2014 and until December 31, 2016, death, or 
12 months after the index overdose, whichever came first. All-cause mortality and opioid-
specific mortality data were extracted from West Virginia Vital Statistics and linked with WV 
Medicaid claim data. The effects of timing of initiation of MOUD, duration of MOUD treatment 
and occurrence of recurrent overdose on patients’ survival rates were examined by Kaplan-Meier 
curves, and evaluated through Cox proportional hazard models in a sequential process, while 
accounting for other covariates, including age, gender, other drug use disorder (stimulants, 
cannabis, etc.), opioid use, and benzodiazepine use. 
Results 
In the 12-month follow up after the index overdose, 182 (10.7%) experienced at least one 
recurrent overdose, 84 (4.9%) died, of which 45 died of opioid poisoning. A total of 431 people 
(25.3%) received MOUD (buprenorphine, naltrexone or both) at any time and only 125 of them 
initiated MOUD after the index overdose. Compared with no MOUD, those who received 
MOUD were associated with non-significant increased all-cause mortality (adjusted hazard ratio 
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[AHR], 1.14 [CI 0.66, 1.96]) and opioid-specific mortality (AHR, 1.53 [CI 0.79, 2.95]). 
Occurrence of recurrent overdose was associated with non-significant increased all-cause 
mortality (AHR, 1.54 [CI 0.83, 2.86]) and opioid-specific mortality (AHR, 1.80 [CI 0.83, 3.89]). 
Compared to those under age 30, older age groups had significantly higher all-cause mortality 
(age between 30-44, AHR, 2.77 [CI 1.21, 6.31]; age at or over 45, AHR, 5.68 [CI 2.52, 12.80]) 
and diagnosis of other drug use disorder (AHR, 1.54 [CI 0.99, 2.38]). Benzodiazepine use (based 
on filled prescriptions only) post index overdose was significantly associated with increased 
opioid-specific mortality (AHR, 1.89, [CI 0.99, 3.59]). Among people who received any MOUD, 
initiation of MOUD before index overdose was associated with non-significant decreased all-
cause mortality (AHR, 0.62 [CI 0.20, 1.93]) and opioid-specific mortality (AHR, 0.83 [0.22, 
3.11]); duration of treatment over 3 months was associated with non-significant decreased all-
cause mortality (AHR, 0.34 [CI 0.10, 1.22]) and opioid-specific mortality (AHR, 0.46 [0.12, 
1.74]).  
Conclusions 
Our study found that people who had had an overdose and then received any types of MOUD 
post overdose had higher all-cause mortality rates and opioid-specific mortality rates than those 
who did not. This is in contrast with other studies, which may be due to the fact that in a state 
with poor access to services, and those receiving MOUD had OUD of a higher severity. 
However, among people who received any MOUD at any time, those who initiated MOUD early 
and those who stayed in the MOUD for over three months had better survival outcomes. Older 
age was significantly associated with high all-cause mortality rate but low MOUD receipt rates. 
Benzodiazepine use and comorbid other drug use disorder increased risk of mortality. In order to 
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prevent future mortality among people who experience an opioid overdose, it is critical to 
provide them access to MOUD in time and make sure they stay in treatment. 
 
4.2 Introduction 
West Virginia (WV) is in the midst of an opioid overdose crisis with a nationally leading 
overdose mortality rate of 58 per 100,000 as of 2017, almost 3 times the U.S. average (Scholl et 
al., 2019)1. Since 2015, potent fentanyl and fentanyl analogs were greatly involved and drove a 
sharp increase in the WV fatal opioid overdose (Dai et al., 2019)2. However, tracing non-fatal 
overdose is more difficult as until recently under West Virginia state law overdose was not a 
reportable condition and only required overdose reporting quarterly (Davis et al., 2018)3. In order 
to curb the opioid crisis, WV preceded the Affordable Care Act (ACA) and expanded Medicaid 
coverage staring on January 2014 (Saloner et al., 2019)4. The expansion mainly provided health 
insurance to non-disabled adults with incomes below 138% of the federal poverty level—a 
population with an elevated risk of opioid overdose. By the time of early 2016, over 50% of 
newly enrolled WV Medicaid beneficiaries were of expansion eligibility, compared to the pre-
ACA monthly Medicaid average (KFF 2016; KFF 2018)5,6. Medicaid enrollees have an 
estimated 3-times higher risk of opioid overdose (Sharp and Melnik, 2015)7, and has been 
identified as a high-risk population for fatal opioid overdose by Centers for Disease Control and 
Prevention (CDC) (Garg et al., 2017; Stoove et al., 2009)8,9. In 2017, approximately 29% of the 
WV population were covered by Medicaid, but overdose decedents were more likely to be 
enrolled in Medicaid (71%) in the 12 months prior to their death (KFF 2018; WVDHHR 
2016)5,10, which makes WV Medicaid an excellent setting to evaluate the effectiveness of 
MOUD on addressing opioid overdose. However, data on the association between MOUD 
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treatment and mortality after a nonfatal overdose have not been evaluated in WV, which is a 
predominately rural state with a lower social-economic status compared to Pennsylvania an 
Massachusetts, where MOUD has been shown effectively in reducing mortality (Larochelle et 
al., 2018; Suffoletto and Zeigler, 2020)11,12.  
Three Medications for OUD (MOUD) are proven treatment options (based on randomized 
controlled trials) in reducing drug use, compulsive drug seeking, substance use relapse, overdose 
and mortality (Sharp et al. 2018; Schwartz et al. 2013; Rudd 2016; Banta-Green et al. 2017; 
Zoorob 2019; Leshner and Mancher 2019)13-18. Buprenorphine is thought to be safer than 
methadone, a full opioid agonist, since a partial agonist is less likely to induce respiratory 
depression (Kimber et al., 2015)19. Naltrexone, an opioid antagonist, blocks the action of opioids 
and thus prevents patients from dying of respiratory depression (Volkow et al., 2014)20. One 
recent systematic review and meta-analysis of 30 observational cohort studies identified a 
significant protective effect in reducing all-cause and overdose mortality among people who 
received any types of MOUD, especially during the time receiving MOUD (Ma et al., 2018)21. 
However, the mortality rate after opioid substitution treatment with buprenorphine was 
significantly higher, and the mortality rate after naltrexone treatment was significantly lower. 
However, another systematic review and meta-analysis of 19 observational cohort studies 
showed quite the opposite conclusion (Sordo et al., 2017)22, as substantial reductions in all-cause 
and overdose mortality for buprenorphine was identified, and the effect of naltrexone on 
mortality was unclear (Lincoln et al., 2018; Lee et al., 2017; Kelty and Hulse, 2012; Gibson and 
Degenhardt, 2007)23-26. Both reviews confirmed that with longer retention time in MOUD 
treatment, the mortality rate gets lower (Ma et al., 2018; Sordo et al., 2017)21,22. 
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However, those studies failed to account the effect of repeated overdose on mortality. Persons 
experiencing nonfatal overdose are at increased risk of overdose death (Coffin et al. 2007)27. A 
most recent systematic review and meta-analysis included 75 studies, suggesting a weak but 
positive relationship between non-fatal overdose and drug-related deaths (Colledge et al., 
2019)28, and this relationship was further quantified by a cohort study with over 10,000 patients, 
suggesting that a history of non-fatal overdose increased the risk of subsequent non-fatal 
overdose (1.57, 95% CI 1.42-1.73) and fatal overdose (1.43, 95%CI 1.12-1.82) (Thylstrup et al., 
2020)29.  
Many studies, including systematic reviews with meta-analysis have determined risk factors 
associated with drug-related deaths. Commercially insurance claim data suggested that over 90% 
of people received opioids even after an overdose (Larochelle et al., 2016)30, and continuous 
receipt of opioid after overdose is associated with high risk for recurrent overdose (Okie, 2010; 
Paulozzi et al., 2011)31,32. As a known risk factor leading to opioid overdose, benzodiazepines 
use was common among opioid users, and increasingly involved in opioid analgesic overdose 
deaths from 18% in 2004 to 31% in 2011 (Thylstrup et al., 2020; Garg et al., 2017; Olfson et al., 
2018; Jones et al., 2015)8,29,33,34. Psychiatric conditions including anxiety, bipolar, depression, 
alcohol use disorder and other drug use disorders (stimulants, cannabis related) were prevalent 
among opioid users and were strongly associated with opioid-related mortality (Suffoletto and 
Zeigler, 2020; Olfson et al., 2018; Bohnert et al., 2012; Webster et al., 2017; Brady et al., 
2017)12, 35-38. Medicaid data from 45 states showed that over a third of decedents experienced a 
non-fatal overdose were diagnosed with drug use disorders, a fifth were diagnosed with anxiety, 
almost a quarter were diagnosed with depression, and about an eighth were diagnosed with 
bipolar and alcohol use disorder in the last 12 months of life (Olfson et al., 2018)33.  
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Considering the substantial burden of the chronic nature of OUD, repeated overdoses and 
psychiatric comorbidities among people who had overdosed, it is important to gain a deeper 
understanding of the circumstances that influence fatal and nonfatal opioid overdoses. Previous 
studies (Larochelle et al., 2018; Suffoletto and Aeigler et al., 2020)11,12 have shown that survival 
modelling approach could be used to examine recurrent opioid overdoses and how changes in 
receipt of MOUD following a non-fatal overdose among the WV Medicaid population affect risk 
of mortality. To achieve the goal, a survival cohort was established and identified from people 
who experienced an opioid overdose, and any receipts of MOUD and recurrent overdose 
associated with the cohort were described. The ultimate goal was to determine whether time-
dependent MOUD, including initiation and duration of MOUD, and recurrent overdose were 
associated with reduced risk for all-cause mortality and opioid-related mortality. 
4.3 Methods 
Study Design and Data Source 
A WV Medicaid overdose cohort was selected and analyzed for survival outcome as described in 
Chapter 3. A Common Data Model (CDM) was created by WV Medicaid to incorporate an 
extensively cleaned subset of WV Medicaid data that was designed to study opioid-related 
measures.  The CDM included WV Medicaid data from 2014 to 2016 and excluded about 20% 
of people who had dual-eligibility with Medicare, as Medicare is the primary payer and 
Medicaid does not include all claims from this group. An overdose cohort was then created from 
CDM by selecting continuously enrolled persons ages 18 to 64 with at least one nonfatal 
overdose event. The first identified nonfatal overdose was selected from emergency department 
(ED) visits or hospitalization after a 12-month observation, and recorded as the index overdose 
using ICD-9 (965.00-965.02, 965.09, E850.0-E850.2) or ICD-10 (X40-X44, X60-X64, X85, 
 74 
 
Y10-Y14) (Appendix A). The retrospective cohort follow-up starts with the index overdose, and 
ends with death or 12 months after the index (Figure 1). 
Mortality data was obtained from WV Vital Statistics from 2014 to 2019, and West Virginia 
Medicaid claims data was obtained from WV Medicaid. The two datasets were linked by unique 
person identification number. For each death, the mortality data include date of death, manner of 
death, ICD-10 coded underlying cause of death and immediate causes of death. The ICD-10 
codes used to identify opioid-specific deaths are listed in Appendix A (Olfson et al., 2018)33. 
These ICD-9 codes were validated with 81% positive predictive values for identifying fatal or 
nonfatal opioid overdose occurred before October, 2015 (Green et al., 2017)39. Another study 
suggested that ICD-10 codes are able to capture more opioid-related hospitalizations that were 
otherwise missed by ICD-9 codes (Heslin et al., 2017)40. Multiple opioid overdoses that occurred 
during one hospitalization interval (admission and discharge date) were counted as one overdose 
event. Two overdoses recorded within two days were also accounted as one overdose event. 
Thus, a recurrent overdose event was defined as one occurring at least two days after the 
previous overdose (avoid potential carry-on effect from previous overdose). The cohort further 
excluded those who died within 30 days of index overdose (make sure every subject had at least 
one-month follow up) and patients with any cancer diagnosis (avoid confounding effect from 
cancer) at any time of cohort. The ICD -9 and ICD-10 codes used to identify cancer were listed 
in Appendix A. Missing values were checked for age and gender and no one was excluded for 
this reason.    
This study was reviewed and approved by the Institutional Review Board (protocol number: 
1711862183A001) at the West Virginia University, Morgantown, WV.  
Key Variables 
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The primary outcomes of interest in this study were all-cause mortality and opioid-specific 
mortality in the 12-month follow up. The main exposures were receipt of MOUD and occurrence 
of recurrent overdose. The receipt of MOUD was identified from both pharmacy datasets using 
National Drug Codes (NDC), and from inpatient and outpatient datasets using the Healthcare 
Common Procedure Coding System (HCPCS) codes. The first date of receipt of MOUD was 
identified and compared to the date of index overdose to determine the presence or absence of 
baseline status. Duration of MOUD was calculated as cumulative days in treatment and then 
dichotomized by median value. The types of medication use were separated into three groups: 
buprenorphine use only, naltrexone use only and mixed group. 
Potential confounding variables were also examined. Patients’ age and gender were obtained 
from Medicaid enrollment files. Age was categorized into 3 groups: 18 to 29 years, 30 to 44 
years and 45 year or older. Post index overdose prescription of opioids and benzodiazepines 
were also identified and dichotomized into presence or absence. Psychiatric diagnosis including 
anxiety, depression, bipolar, alcohol use disorder and other drug use disorder (stimulants, 
cannabis, etc) were also identified. 
Statistical Analysis 
Kaplan–Meier method was used to examine survival trends of all-cause mortality by receipt of 
MOUD and number of overdoses. A log-rank test was used to assess the difference of time-to-
events between subgroups.  
Univariate and multivariable Cox proportional hazard models were applied to evaluate MOUD 
effectiveness on reducing both all-cause mortality and opioid-specific mortality, while adjusting 
for other potential confounders, including the prescription of opioids and benzodiazepines post 
index overdose, presence of anxiety, depression, bipolar, alcohol use disorder, and other drug use 
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disorder. Multivariable models were developed in a sequential approach, by first only modelling 
MOUD presence or absence, and then specifically modelling the subgroup with any MOUD 
presence. Timing of initiation of MOUD, duration of MOUD and recurrence of overdose were 
added into the subgroup Cox model to have a comprehensive evaluation of MOUD through 
survival approach. To have a better understanding of model results, in-depth investigations into 
the subgroup analyses were carried out.  
4.4 Results 
The study identified a survival cohort after an index overdose with 1703 subjects, who had 2001 
records of overdoses (1.17 overdose per person on average) in the 12-month follow up. For 
people in the cohort (Table 1), 47% were male, 42% aged between 29 to 44, 32% aged at or over 
45, and 59% were enrolled as Medicaid expansion category. As for comorbid mental health 
conditions, 177 (10.4%) were diagnosed with anxiety, 213 (12.5%) had depression, 76 (4.5%) 
had bipolar, 72 (4.2%) had alcohol use disorder, and 524 (30.8%) had other drug use disorder. A 
total of 182 (10.7%) patients experienced at least one repeated overdose in the 12-month follow 
up; of whom 23 patients had two repeated overdoses, 8 patients had three repeated overdoes, and 
4 patients had four repeated overdoses. During the one-year follow up, 84 (4.9%) persons died of 
whom 45 of them were died from opioid (Table 2). Further, among those deaths, 45 (53.6%) 
were unintentional, 33 (39.3%) were natural, 5 (6.0%) were suicide and 1 (1.2%) was 
undetermined. People who died within 12-month follow up were older than those who were 
alive, were more likely to be enrolled in disabled and expansion category, and had higher rates of 
psychiatric conditions. In addition, 21 (46.7%) of those who died from opioids had OUD 
diagnosis, compared to 605 (37.4%) of those who were alive after 1-year follow up had 
diagnosed OUD. 
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Only 431 (25.3%) patients had ever received MOUD either before or after the overdose, among 
whom 273 (63.3%) received buprenorphine (hydrochloride and/or Suboxone), 78 (18.1%) 
received naltrexone, and 80 (18.6%) received both medications. There were 251(58.2%) persons 
with 733 OUD diagnosis among those who had ever received MOUD, and 418 (32.9%) persons 
with 989 OUD diagnosis among those who had never received any MOUD. The OUD diagnosis 
rate is significantly higher among people who received any MOUD (p<0.0001). In addition, the 
average number of OUD diagnosis records among MOUD recipients was 2.9, which is 21% 
higher than 2.4 among non-MOUD population. 
MOUD and non-MOUD groups 
The Kaplan-Meier survival curve in Figure 2 shows that people who did not receive any MOUD 
had a higher decreased survival rates, compared with people who received MOUD at any time 
(0.948 vs. 0.958). In the unadjusted Cox model, compared with no MOUD, receipt of MOUD 
was associated with non-significant decrease in all-cause mortality (adjusted hazard ratio [AHR], 
0.80 [CI 0.48, 1.35]) and non-significant increase in opioid-specific mortality (AHR, 1.33 [CI 
0.71, 2.50]). In the adjusted multivariable Cox model (Table 3), compared with no MOUD, 
receipt of MOUD was associated with non-significant increase in all-cause mortality (AHR, 1.14 
[CI 0.66, 1.96]) and opioid-specific mortality (AHR, 1.53 [CI 0.79, 2.95]). Further in the 
subgroup analyses, among people who received any MOUD (Table 4), initiation of MOUD 
before index overdose was associated with non-significant decrease in all-cause mortality (AHR, 
0.62 [CI 0.20, 1.93]) and opioid-specific mortality (AHR, 0.83 [0.22, 3.11]); duration in the 
treatment over 3 month was associated with non-significant decrease in all-cause mortality 
(AHR, 0.34 [CI 0.10, 1.22]) and opioid-specific mortality (AHR, 0.46 [0.12, 1.74]). In another 
subgroup analysis, the study subjects were separated into four mutually exclusive groups: no 
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MOUD, MOUD initiated after index overdose, MOUD initiated and ended before the index 
overdose, and MOUD initiated and lasted through index overdose. Compared with the first three 
groups, the last group had non-significantly decrease in all-cause mortality (AHR, 0.59 [CI 0.14, 
2.49]) and non-significant increase in opioid-specific mortality (AHR, 0.94 [CI 0.22, 4.08]). 
Single vs. Multiple overdose groups 
The Kaplan-Meier survival curve in Figure 3 shows that people who experienced a recurrent 
overdose had a more rapid decreased survival rate, compared with people who only experienced 
one overdose (0.934 vs. 0.953). In the unadjusted Cox model, occurrence of a recurrent overdose 
was associated with non-significant increase in all-cause mortality (AHR, 1.40 [CI 0.76, 2.58]) 
and opioid-specific mortality (AHR, 1.81 [CI 0.85, 3.89]). In the adjusted multivariable Cox 
model (Table 3), occurrence of recurrent overdose was associated with non-significant increase 
in all-cause mortality (AHR, 1.54 [CI 0.83, 2.86]) and opioid-specific mortality (AHR, 1.80 [CI 
0.83, 3.89]). The receipt of MOUD was significantly associated with occurrence of recurrent 
overdose (p = 0.0377), with 58 (13.5%) had another overdose in the MOUD group, compared 
with 124 (9.7%) had another overdose in the no MOUD group. In unadjusted Cox model with 
occurrence of recurrent overdose as outcome event, compared with no MOUD, receipt of 
MOUD had significantly increased hazard ratio at 1.42 [CI 1.04, 1.93]. In the subgroup analysis, 
among those who received any MOUD, solely received buprenorphine was significantly 
associated with occurrence of recurrent overdose (HR, 1.43 [CI 0.99, 2.06]). 
Among the covariates, older age (age between 30- 44, AHR, 2.77 [CI 1.21, 6.31]; age at or over 
45, AHR, 5.68 [CI 2.52, 12.80]) and diagnosis of other drug use disorder (AHR, 1.54 [CI 0.99, 
2.38]) were significantly associated with increased all-cause mortality. Diagnosis of other drug 
use disorder (AHR, 1.69, [CI 0.93, 3.07]) and being male (AHR, 1.69, [CI 0.93, 3.07]) were 
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associated with marginally significantly increased opioid-specific mortality. Benzodiazepine 
prescription post index overdose was associated with marginally significantly increased all-cause 
mortality (AHR, 1.55 [CI 0.96, 2.53]) and significantly increased opioid-specific mortality 
(AHR, 1.89, [CI 0.99, 3.59]).  
4.5 Discussion 
In a cohort of 1703 persons who had a nonfatal opioid overdose between 2015 and 2016 in West 
Virginia, the rate of all-cause mortality at 12 months following overdose was 4.9% and the rate 
of opioid-specific mortality was 2.6%. A total of 431 (25.3%) persons received MOUD 
(buprenorphine, naltrexone or both). Specifically, 125 (29%) initiated MOUD after the index 
overdose. Compared with no MOUD, those who received MOUD at any time was associated 
with non-significant increased all-cause mortality (adjusted hazard ratio [AHR], 1.14 [CI 0.66, 
1.96]) and opioid-specific mortality (AHR, 1.53 [CI 0.79, 2.95]). 
To the best of our knowledge, this is the first West Virginia based study to use a survival 
approach to examine the association between MOUD and mortality after a nonfatal opioid 
overdose in the Medicaid setting, and taking recurrent overdose into consideration. Our finding 
that the use of MOUD actually increased mortality although not significantly is in conflict with 
other studies that found a protective effect of using MOUD (Larochelle et al., 2018; Kelty and 
Hulse et al., 2016; Frazier et al., 2017)12,25,41,, one possible explanation is that receipt of MOUD 
is an indicator for those identified with higher severity of OUD. In addition, WV has much less 
access to treatment and this effect will be investigated further. Additionally, the short length of 
study follow-up period and small sample size in survival analyses also limited the statistical 
power to reach a significant level. The all-cause mortality rate in our study is very close to 
another study analyzing the Massachusetts population who survived a non-fatal overdose (4.9 vs. 
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our 4.7), with 10 times larger sample size around similar study period (from 2012 to 2014) 
(Larochelle et al., 2018)12. In comparison with the WV Medicaid population, both the MA cohort 
(Larochelle et al., 2018)12 and a Pennsylvania Medicaid cohort (Frazier et al., 2017)41 had a 
much larger proportion of people who received any MOUD both prior to (26% or 29% vs. our 
18%) or after the index overdose (30% or 33% vs. our 7%), which is a huge difference. Notably, 
the data in our study period is 2014-2016 which is after WV Medicaid expansion started January 
2014 when in theory MOUD therapy should be more accessible; whereas the data analyzed in 
MA was between 2012 and 2014. The huge difference of proportion of people receiving MOUD 
might well explained why the MA study demonstrated significant association between the use of 
buprenorphine or methadone and reductions in all-cause and opioid-specific mortality, while in 
WV only those with the most severe or recognizable OUD received treatment. In addition, those 
who died from opioids did have a higher rates of OUD diagnosis and significantly higher number 
of OUD diagnosis records, suggesting that receipt of MOUD is an indicator for those identified 
with higher severity of OUD. 
In this study, 10.7% of those having their index overdose had a recurrent overdose within 12 
months following an index overdose. The rate of recurrent overdose varies across different 
studies. The Pennsylvania study found that 14.9% of patients who experienced a non-fatal 
overdose had a recurrent overdose in 12 months (Suffoletto and Zeigler et al., 2020)12. An 
Indiana study suggested that the prevalence of repeated nonfatal overdose resulting in emergency 
department (ED) visits increased almost four-fold between 9% in 2012 to 35% in 2017, and on 
average 10.9% between 2014 and 2017 (Lowder et al., 2020)42. ED data from two other states 
suggested that 10.0% of drug-related ED visits led to near-fatal events (Hasegawa et al., 2014)43. 
In a national study among 2848 commercially insured patients, the rate of repeated overdose 
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after an index overdose was 7% in a year, and 17% in two years for patients receiving high 
dosages of opioids (Larochelle et al., 2016)30. Medicaid data from 45 states found that during the 
12 months after an initial nonfatal overdose, the rate of subsequent overdose was 29.5 per 100 
person-years and that of fatal opioid overdose was 1.15 per 100 person-years (Olfson et al., 
2018)33. The reason why the rate of recurrent overdose is relatively low among WV Medicaid 
population might be that claim data was not able to capture all overdose. Due to spatial isolation 
and limited medical resources, many opioid overdose might not result in medical care seeking 
attempts, and end up with either death or rescued in the community by naloxone (Saloner et al., 
2018)4. The lack of reported overdose is not unique in WV, though (Larochelle et al., 2018)12. 
Strengths and limitations 
MOUD has shown to be effective in reducing mortality in other states, and our study was the 
first West Virginia based study to evaluate MOUD effectiveness among overdose population in 
the WV Medicaid setting. The study also examined the effect of risk factors on mortality among 
overdose population, including exposure to prescription opioids, benzodiazepines and psychiatric 
diagnosis. The limitations of the current study, especially the small sample size and limited 
follow up period, indicate the need for more research to have a better understanding of how time-
dependent MOUD and repeated overdoses affect people’s survival outcomes in West Virginia. 
First the generalizability of the study was largely constrained because of the short length of study 
follow-up period, which only followed the cohort for 1 year as this was used in recently 
published studies (Larochelle et al., 2018; Suffoletto and Zeigler et al., 2020)11,12. Studies 
applying survival approaches usually have a follow up period over three years to reach a decent 
sample size and statistical power, therefore, another two to three years data are needed for a 
comprehensive study in WV as the state only had a small number of overdoses over the study 
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period: 1703 compared to 17568 in the Massachusetts study (Larochelle et al., 2018)11. Second, 
the study was unable to evaluate the effect of methadone on survival rates since methadone was 
not covered by WV Medicaid until recently in January 1, 2018. A third limitation is that the 
Medicaid data in the CDM we used does not include all patients in Medicaid as it already 
excluded persons with dual-eligibility with Medicare, which accounts for about 20% of overall 
Medicaid population. 
Conclusions 
In conclusion, while this study found that in some groups receiving MOUD that it is likely to be 
effective in lowering mortality risk in West Virginia, the fact that MOUD recipients were more 
likely to have OUD with a higher severity and that less of the population received treatment 
likely hampered the effectiveness of treatment. In addition, limited sample size prevented us 
from reaching sufficient statistical power. The findings from this study confirmed the 
contribution of continuous efforts by state agencies to expand Medicaid eligibility and MOUD 
access. Additional data and future research are needed to guide the timely receipt of MOUD for 
the patients in urgent need. The state agencies should consider necessary policy change to 
continue to expand treatment access, Medicaid eligibility, and also provide people who had 
opioid overdoses to receive comprehensive and effective treatments and supports. 
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Tables and Figures 
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Figure 1. Flow chart of case selection of opioid overdose cohort 
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Figure 2. Kaplan-Meier Survival Curve among receipt of MOUD group and no MOUD 
groups (N = 1703) 
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Figure 3. Kaplan-Meier Survival Curve among single overdose group and multiple 
overdose groups (N = 1703) 
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Table 1 Demographic and Medicaid-related Characteristics among Opioid Overdose 
Cohort Comparing those Alive and Dead at end of 1 year (N = 1703) 
 
  Overall Alive Dead 
Number of people 1703 1619 (95.1)a 84 (4.9) a 
Number of overdose 2001 1905 (95.2) a 96 (4.8) a 
  2015 729 693 (36.4) b 36 (37.5) b 
  2016 1272 1212 (63.6) b 60 (62.5) b 
Age (mean ± std) 38.2 ± 11.6 37.9 ± 11.5 45.4 ± 10.5 
  18 - 29 459 (27.0) 452 (27.9) 7 (8.3) 
  30 - 44 708 (41.6) 677 (41.8) 31 (36.9) 
  45 - 64 536 (31.5) 490 (30.3) 46 (54.8) 
Male 802 (47.1) 763 (47.1) 39 (46.4) 
Race    
  Non-Hispanic white 1506 (88.4) 1433 (88.5) 73 (86.9) 
  Non-Hispanic black 60 (3.5) 56 (3.5) 4 (4.8) 
  Hispanic 28 (1.6) 28 (1.7) 0 (0.0) 
  Others 109 (6.4) 102 (6.3) 7 (8.3) 
Eligibility category    
  Pregnant Women 31 (3.0) 30 (3.0) 1 (2.9) 
  Children 46 (4.5) 45 (4.5) 1 (2.9) 
  Disabled Adults 95 (9.2) 92 (9.2) 6 (17.7) 
  Non-Disabled Adults 248 (24.0) 240 (24.0) 3 (8.8) 
  Expansion Adults 614 (59.4) 594 (59.4) 23 (67.7) 
Psychiatric conditions    
  Anxiety 177 (10.4) 164 (10.1) 13 (15.5) 
  Depression 213 (12.5) 198 (12.2) 15 (17.9) 
  Bipolar 76 (4.5) 72 (4.5) 4 (4.8) 
  Alcohol use disorder 72 (4.2) 66 (4.1) 6 (7.1) 
  Drug use disorder 524 (30.8) 488 (30.1) 36 (42.9) 
Note: a percentage was calculated by row;   
b percentage was calculated by number of overdose.   
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Table 2. Cause of death among the analytical cohort (N = 84) 
ICD10 Underlying cause of death Count Percent 
A310 Pulmonary mycobacterial infection 1 1.19 
B182 Chronic viral hepatitis C 1 1.19 
B24 Unspecified human immunodeficiency virus [HIV] disease 1 1.19 
C959 Leukemia  1 1.19 
E109 Insulin-dependent diabetes mellitus 1 1.19 
E115 Non-insulin dependent diabetes mellitus 1 1.19 
E119 Non-insulin dependent diabetes mellitus 1 1.19 
E141 Unspecified diabetes mellitus 1 1.19 
E149 Unspecified diabetes mellitus 1 1.19 
E668 Other obesity 1 1.19 
G35 Multiple sclerosis  1 1.19 
G931 Anoxic brain damage, not elsewhere classified 1 1.19 
I119 Hypertensive heart disease without (congestive) heart failure 1 1.19 
I219 Acute myocardial infarction, unspecified  1 1.19 
I250 Atherosclerotic cardiovascular disease, so described 1 1.19 
I251 Arteriosclerotic heart disease  1 1.19 
I259 Chronic ischaemic heart disease, unspecified 1 1.19 
I429 Cardiomyopathy, unspecified 1 1.19 
I499 Cardiac arrhythmia, unspecified 1 1.19 
I500 Congestive heart failure 1 1.19 
I709 Generalized and unspecified atherosclerosis 1 1.19 
J440 Chronic obstructive pulmonary disease with acute lower respiratory infection 1 1.19 
J449 COPD 2 2.38 
K559 Vascular disorder of intestine, unspecified 1 1.19 
K565 Intestinal adhesions [bands] with obstruction 1 1.19 
K703 Alcoholic cirrhosis of liver 1 1.19 
K746 Other and unspecified cirrhosis of liver 1 1.19 
K769 Liver disease, unspecified 1 1.19 
K861 Other chronic pancreatitis 1 1.19 
N179 Acute renal failure, unspecified 1 1.19 
N390 Urinary tract infection, site not specified 1 1.19 
R99 Other ill-defined and unspecified causes of mortality 1 1.19 
V059 Pedestrian injured in collision with railway train or railway vehicle 1 1.19 
V892 Person injured in unspecified motor-vehicle accident, traffic 1 1.19 
X41 
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, 
antiparkinsonism and psychotropic drugs, not elsewhere classified 1 1.19 
X42 
Accidental poisoning by and exposure to narcotics and psychodysleptics 
[hallucinogens], not elsewhere classified 6 7.14 
X44 
Accidental poisoning by and exposure to other and unspecified drugs, 
medicaments and biological substances 35 41.67 
X61 
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, 
antiparkinsonism and psychotropic drugs, not elsewhere classified 1 1.19 
X62 
Intentional self-poisoning by and exposure to narcotics and psychodysleptics 
[hallucinogens], not elsewhere classified 1 1.19 
X70 Intentional self-harm by hanging, strangulation and suffocation 1 1.19 
X72 Intentional self-harm by handgun discharge 2 2.38 
Y14 
Poisoning by and exposure to other and unspecified drugs, medicaments and 
biological substances, undetermined intent 1 1.19 
Y850 Sequelae of motor-vehicle accident 1 1.19 
 
 89 
 
Table 3 Multivariable Cox proportional hazards analyses for all-cause and opioid-specific mortality by receipt of medications 
for opioid use disorder (MOUD) in12 months following index nonfatal opioid overdose (N = 1703). 
 
Predictor 
All-cause Mortality Opioid-specific Mortality 
Hazard 
Ratio 
95% Confidence Interval of 
Hazard Ratio 
P-
value 
Hazard 
Ratio 
95% Confidence Interval of 
Hazard Ratio 
P-
value 
MOUD 1.14 0.66 1.96 0.64 1.53 0.79 2.95 0.21 
Recurrent overdose 1.54 0.83 2.86 0.17 1.80 0.83 3.89 0.14 
Opioid prescription 0.67 0.42 1.08 0.10 0.63 0.33 1.20 0.16 
Benzodiazepine 
prescription 1.55 0.96 2.53 0.08 1.89 0.99 3.59 0.05 
Other drug use 
disorder 1.54 0.99 2.38 0.05 1.69 0.93 3.07 0.08 
Age between 30 to 44 2.76 1.21 6.31 0.02 1.90 0.80 4.48 0.14 
Age at or over 45 5.68 2.52 12.80 <0.01 2.09 0.84 5.24 0.12 
Male 1.01 0.66 1.55 0.96 1.69 0.93 3.07 0.09 
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Table 4 Multivariable Cox proportional hazards analyses for all-cause and opioid-specific mortality among recipients of 
medications for opioid use disorder (MOUD) in12 months following index nonfatal opioid overdose (N = 431). 
 
Predictor 
All-cause Mortality Opioid-specific Mortality 
Hazard 
Ratio 
95% Confidence Interval of 
Hazard Ratio 
P-
value 
Hazard 
Ratio 
95% Confidence Interval of 
Hazard Ratio 
P-
value 
Receipt of MOUD at 
baseline 0.62 0.20 1.93 0.41 0.83 0.22 3.11 0.79 
Duration in MOUD 
over 88 days 0.34 0.10 1.22 0.10 0.46 0.12 1.74 0.25 
Recurrent overdose 1.36 0.44 4.24 0.60 2.09 0.64 6.87 0.22 
Opioid prescription 0.37 0.12 1.12 0.08 0.36 0.10 1.28 0.12 
Benzodiazepine 
prescription 2.05 0.74 5.70 0.17 1.81 0.56 5.89 0.32 
Other drug use 
disorder 2.34 0.87 6.33 0.09 1.84 0.59 5.78 0.30 
Age between 30 to 44 1.31 0.37 4.65 0.67 1.19 0.32 4.40 0.79 
Age at or over 45 3.65 1.03 12.94 0.04 2.28 0.55 9.53 0.26 
Male 0.97 0.38 2.50 0.95 0.87 0.30 2.55 0.80 
 
 
 
 
 
 91 
 
References: 
1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose 
Deaths - United States, 2013-2017. Morbidity and Mortality Weekly Report. 
2018;67(5152):1419-1427. 
2. Dai Z, Abate MA, Smith GS, Kraner JC, Mock AR. Fentanyl and fentanyl-analog 
involvement in drug-related deaths. Drug and Alcohol Dependence. 2019;196:1-8. 
3. Davis CS, Green,TC, Hernandez-Delgado H, Lieberman AJ. Status of US State Laws 
Mandating Timely Reporting of Nonfatal Overdose. American Journal of Public Health. 
2018;108(9):1159-1161. 
4. Saloner B, Landis R, Stein BD, Barry CL. The Affordable Care Act In The Heart Of The 
Opioid Crisis: Evidence From West Virginia. Health affairs. 2019;38(4):633-642. 
5. Kaiser Family Foundation (KFF). Medicaid’s Role in Addressing the Opioid Epidemic. 
2018. https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/. 
Accessed 5.25.2019. 
6. Kaiser Family Foundation (KFF). Medicaid’s Role in West Virginia. 2017. 
https://www.kff.org/medicaid/fact-sheet/medicaids-role-in-west-virginia/. Accessed 
3.1.2020. 
7. Sharp MJ, Melnik TA. Poisoning deaths involving opioid analgesics—New York State, 
2003–2012. Morbidity and Mortality Weekly Report. 2015;64(14):377. 
8. Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of opioid use and risk of opioid 
overdose death among Medicaid patients. Medical Care. 2017;55(7):661-668. 
9. Stoové MA, Dietze PM, Jolley D. Overdose deaths following previous non‐fatal heroin 
overdose: record linkage of ambulance attendance and death registry data. Drug and 
Alcohol Review. 2009;28(4):347-352. 
10. West Virginia Department of Health & Human Resources (WVDHHR). 2016 West 
Virginia overdose fatality analysis. 2017. 
https://dhhr.wv.gov/bph/Documents/ODCP%20Reports%202017/2016%20West%20Virg
inia%20Overdose%20Fatality%20Analysis_004302018.pdf. Accessed 7.7.2019. 
11. Suffoletto B, Zeigler A. Risk and protective factors for repeated overdose after opioid 
overdose survival. Drug and Alcohol Dependence. 2020;209:107890. 
12. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after 
nonfatal opioid overdose and association with mortality: a cohort study. Annals of 
internal medicine. 2018;169(3):137-145. 
13. Sharp A, Jones A, Sherwood J, Kutsa O, Honermann B, Millett G. Impact of Medicaid 
Expansion on Access to Opioid Analgesic Medications and Medication-Assisted 
Treatment. American Journal of Public Health. 2018;108(5):642-648. 
14. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin 
overdose deaths in Baltimore, Maryland, 1995-2009. American Journal of Public Health. 
2013;103(5):917-922. 
15. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose 
deaths—United States, 2010–2015. Morbidity and Mortality Weekly Report. 2016;65. 
16. Banta-Green CJ, Coffin PO, Schoeppe JA, Merrill JO, Whiteside LK, Ebersol AK. 
Heroin and pharmaceutical opioid overdose events: Emergency medical response 
characteristics. Drug and Alcohol Dependence. 2017;178:1-6. 
 92 
 
17. Zoorob M. Fentanyl shock: The changing geography of overdose in the United States. 
International Journal of Drug Policy. 2019;70:40-46. 
18. Mancher M, Leshner AI, National Academies of Sciences, Engineering, and Medicine.  
Medications for Opioid Use Disorder in Various Treatment Settings. Medications for 
Opioid Use Disorder Save Lives. National Academies Press (US); 2019. 
19. Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid 
substitution therapy with methadone versus buprenorphine: a retrospective cohort study. 
The Lancet Psychiatry. 2015;2(10):901-908. 
20. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the 
opioid-overdose epidemic. New England Journal of Medicine. 2014;370(22):2063-2066. 
21. Ma J, Bao Y-P, Wang R-J, et al. Effects of medication-assisted treatment on mortality 
among opioids users: a systematic review and meta-analysis. Molecular Psychiatry. 
2019;24(12):1868-1883. 
22. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution 
treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical research 
ed). BMJ.  2017;357:j1550. 
23. Lincoln T, Johnson BD, McCarthy P, Alexander E. Extended-release naltrexone for 
opioid use disorder started during or following incarceration. Journal of substance abuse 
treatment. 2018;85:97-100. 
24. Lee JD, Nunes Jr EV, Novo P, et al. Comparative effectiveness of extended-release 
naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a 
multicentre, open-label, randomised controlled trial. The Lancet. 2018;391(10118):309-
318. 
25. Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients 
treated with oral or implant naltrexone for problematic opiate use. Addiction. 
2012;107(10):1817-1824. 
26. Degenhardt L, Gibson A, Mattick RP, Hall W. Depot naltrexone use for opioid 
dependence in Australia: large-scale use of an unregistered medication in the absence of 
data on safety and efficacy. Drug and alcohol review. 2008; 27(1): 1-3. 
27. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection 
drug users at risk of nonfatal overdose. Academic Emergency Medicine. 2007;14(7):616-
623. 
28. Colledge S, Peacock A, Leung J, et al. The prevalence of non-fatal overdose among 
people who inject drugs: a multi-stage systematic review and meta-analysis. International 
Journal of Drug Policy. 2019; 73:172-184. 
29. Thylstrup B, Seid AK, Tjagvad C, Hesse M. Incidence and predictors of drug overdoses 
among a cohort of> 10,000 patients treated for substance use disorder. Drug and Alcohol 
Dependence. 2020;206:107714. 
30. Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF. Opioid 
prescribing after nonfatal overdose and association with repeated overdose: a cohort 
study. Annals of Internal Medicine. 2016;164(1):1-9. 
31. Okie S. A flood of opioids, a rising tide of deaths. New England Journal of Medicine. 
2010;363(21):1981-1985. 
32. Paulozzi LJ, Kilbourne EM, Desai H. Prescription drug monitoring programs and death 
rates from drug overdose. Pain Medicine. 2011;12(5):747-754. 
 93 
 
33. Olfson M, Wall M, Wang S, Crystal S, Blanco C. Risks of fatal opioid overdose during 
the first year following nonfatal overdose. Drug and Alcohol Dependence. 2018;190:112-
119. 
34. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment 
Need and Capacity for Opioid Agonist Medication-Assisted Treatment. American 
Journal of Public Health. 2015;105(8):e55-63. 
35. Olfson M, Crystal S, Wall M, Wang S, Liu S-M, Blanco C. Causes of death after nonfatal 
opioid overdose. JAMA Psychiatry. 2018;75(8):820-827. 
36. Bohnert AS, Ilgen MA, Ignacio RV, McCarthy JF, Valenstein M, Blow FC. Risk of death 
from accidental overdose associated with psychiatric and substance use disorders. 
American Journal of Psychiatry. 2012;169(1):64-70. 
37. Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. Risk markers for fatal and non-fatal 
prescription drug overdose: a meta-analysis. Injury Epidemiology. 2017;4(1):24. 
38. Webster LR. Risk factors for opioid-use disorder and overdose. Anesthesia & Analgesia. 
2017;125(5):1741-1748. 
39. Green CA, Perrin NA, Janoff SL, et al. Assessing the accuracy of opioid overdose and 
poisoning codes in diagnostic information from electronic health records, claims data, 
and death records. Pharmacoepidemiology and Drug Safety. 2017;26(5):509-517. 
40. Heslin KC, Owens PL, Karaca Z, Barrett ML, Moore BJ, Elixhauser A. Trends in opioid-
related inpatient stays shifted after the US transitioned to ICD-10-CM diagnosis coding in 
2015. Medical Care. 2017;55(11):918-923. 
41. Frazier W, Cochran G, Lo-Ciganic WH, et al. Medication-Assisted Treatment and Opioid 
Use Before and After Overdose in Pennsylvania Medicaid. JAMA. 2017;318(8):750-752. 
42. Lowder EM, Amlung J, Ray BR. Individual and county-level variation in outcomes 
following non-fatal opioid-involved overdose. J Epidemiol Community Health. 2020. 
43. Hasegawa K, Brown DF, Tsugawa Y, Camargo Jr CA. Epidemiology of emergency 
department visits for opioid overdose: a population-based study. Mayo Clinic 
Proceedings. 2014; 89(4): 462-471. 
 
 
  
94 
 
 
 
 
 
 
 
 
 
Chapter 5 
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5.1 Summary 
This dissertation study consists of three parts each of which are separate papers. The first paper 
described the impact substance abuse has on mortality in West Virginia (WV) and analyzed the 
involvement of fentanyl and fentanyl analogs (FAs) in drug-related deaths in WV from 2005 to 
2017. A WV forensic drug data (FDD) was used to compile all WV drug-related deaths, and the 
results of analyzing the cause of those deaths showed that most of the 8813 drug-related deaths 
were overdoses, with about 11% resulting from transportation/ other injuries in which drugs were 
contributors. Prescription opioid presence (without fentanyl) decreased by 75% from 2005–14 to 
2015–17 (3545 deaths to 859 deaths, respectively), while fentanyl involvement in the deaths 
increased by 122% between these periods (487 to 1082 deaths). Ten FAs were identified (427 
instances) beginning 2015. Alprazolam and ethanol were among the top five most frequently 
identified substances across years. Fentanyl, heroin and cocaine replaced oxycodone, diazepam 
and hydrocodone in the top five drugs found beginning in 2015. When the West Virginia 
Controlled Substance Monitoring Program (WV CSMP) was checked for each decedent, few 
decedents had a prescription recorded for fentanyl after 2015, with fewer prescriptions also 
present for other controlled substances identified. In conclusion, fentanyl involvement increased 
substantially over time in WV drug related deaths from 2005 to 2017, with ten different FAs 
identified since 2015. Prescription opioid presence decreased by about half with fentanyl, heroin, 
ethanol, alprazolam and cocaine constituting the top five identified drugs in these deaths since 
2015. Alprazolam and ethanol were consistently among the top five drugs identified since 2005, 
with increasing methamphetamine involvement. In contrast, the presence of a prescription for 
most controlled substances identified in the deaths has been decreasing, suggesting more 
involvement of illegal drugs in those deaths. Death involving fentanyl and newly identified FAs 
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could represent the “tip of the iceberg” since fentanyl derivatives are often not readily detected, 
since many of them were newly synthesized compounds with unknown chemical structure. 
The second paper involved analysis of the WV Medicaid data and explored the change of 
recurrent opioid overdose and receipt of Medication for Opioid Use Disorder (MOUD) following 
a non-fatal overdose among persons enrolled in West Virginia (WV) Medicaid. Among 513,707 
WV Medicaid beneficiaries from 2014 to 2016, a total of 399,683 (77.8%) were continuously 
enrolled and analyzed in the study. An overdose cohort was created by selecting any people who 
experienced an opioid overdose after a 12-month overdose free period, and removing those who 
died within 30 days of index overdose, or with cancer diagnosis. After removing multiple 
overdose records occurred on the same day or the following day, the final analytical cohort 
included 1703 subjects and 182 (10.7%) experienced at least one recurrent overdose in the 12-
month follow up. Only 431(25.3%) subjects received any MOUD, of whom 273 (63.3%) 
received buprenorphine (hydrochloride and/or Suboxone), 78 (18.1%) received naltrexone, and 
80 (18.6%) received both medications. There were 125 patients who initiated MOUD after the 
index overdose. The median time staying in MOUD treatment was 88 days (range from 2 to 
1094 days). In conclusion, only a quarter of people who experienced an opioid overdose received 
MOUD and half of them stayed in the treatment less than 3 months, suggesting limited 
effectiveness. Although a nonfatal overdose represents an opportunity to initiate MOUD, it was 
certainly under-utilized among WV overdose population. 
The third paper identified associations between time-dependent MOUD and mortality among a 
WV Medicaid overdose cohort, adjusting for recurrent overdose and other risk factors. All-cause 
mortality and opioid-specific mortality data were extracted from West Virginia Vital Statistics 
and linked with WV Medicaid claim data. In the 12-month follow up after the index overdose, 
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182 (10.7%) experienced at least one recurrent overdose, 84 (4.9%) died and 45(53.6%) of these 
died of opioid poisoning. A total of 431 (25.3%) received MOUD (buprenorphine, naltrexone or 
both), and only 125 of them initiated MOUD after the index overdose. Compared with no 
MOUD, MOUD was associated with non-significant increased all-cause mortality (adjusted 
hazard ratio [AHR], 1.14 [CI 0.66, 1.96]) and opioid-specific mortality (AHR, 1.53 [CI 0.79, 
2.95]). Occurrence of recurrent overdose was associated with non-significant increased all-cause 
mortality (AHR, 1.54 [CI 0.83, 2.86]) and opioid-specific mortality (AHR, 1.80 [CI 0.83, 3.89]). 
Older age (age between 30-44, AHR, 2.77 [CI 1.21, 6.31]; age at or over 45, AHR, 5.68 [CI 
2.52, 12.80]) and diagnosis of other drug use disorder, including stimulant, cannabis, sedative 
related disorders (AHR, 1.54 [CI 0.99, 2.38]) were significantly associated with increased all-
cause mortality. A filled prescription for benzodiazepine post index overdose was also 
significantly associated with increased opioid-specific mortality (AHR, 1.89, [CI 0.99, 3.59]). 
Among people who received any MOUD, those who initiated MOUD before index overdose had 
a non-significant decreased all-cause mortality compared to those who initiated MOUD after 
index overdose (AHR, 0.62 [CI 0.20, 1.93]) and opioid-specific mortality (AHR, 0.83 [0.22, 
3.11]); duration of treatment over 3 months was associated with non-significant decreased all-
cause mortality (AHR, 0.34 [CI 0.10, 1.22]) and opioid-specific mortality (AHR, 0.46 [0.12, 
1.74]). In conclusion, people who received any type of MOUD had non-significant higher all-
cause mortality rates and opioid-specific mortality rates, possibly because receipt of MOUD is an 
indicator for those identified with higher severity of OUD. However  those who initiated MOUD 
early and people who stayed in the MOUD for over three months had better survival outcomes 
than others receiving MOUD. Benzodiazepine use and comorbid other drug use disorder 
increased risk of mortality. Age over 44 was also significantly associated with high all-cause 
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mortality but low rate of MOUD receipt. In order to prevent future mortality among people who 
experience an opioid overdose, it is critical to provide them access to MOUD and make sure they 
stay in treatment. 
5.2 Significance 
The overall mortality rate for unintentional drug poisonings in the United States (US) grew 
exponentially in recent years (Jalal et al. 2018)1. There are estimated 72,000 deaths due to drug 
poisoning in 2017 (Hedegaard et al. 2018)2, and opioids are the main driver of the drastically 
increasing drug overdose deaths over the last 20 years, with evolving substance use patterns 
changed drastically over time. WV leads the nation in drug overdose mortality with the highest 
per capita drug overdose mortality rate of 57.8 per 100,000 population as of 2017, almost 3 times 
the US average (Scholl et al. 2018; Hedegaard et al. 2018)2,3. The current state of the opioid 
crisis is attributable to earlier excessive prescribing behaviors, widespread availability of 
inexpensive heroin, and an increase in use of highly potent fentanyl and its analogs (Armenian 
2017; Suzuki and El-Haddad 2017)4,5. The current opioid crisis has strained the capacity of 
health care and social service resources and taken a major toll on individuals, families, 
communities, and counties in WV (Saloner et al. 2019)6. In general, persons experiencing 
nonfatal overdose are at increased risk of overdose death (Coffin et al. 2007)7. This risk is further 
intensifying in states like West Virginia experiencing geographic isolation (Hall et al. 2008)8 and 
having limited medical resources, resulting in tremendous gaps between the need for sustainable 
treatment and the state’s capacity to deliver these options (Jones et al. 2015)9. Therefore, it is of 
great public health importance to rapidly address the opioid overdose problem in WV. 
This study addressed the WV overdose problem through developing a series of studies focusing 
on drug-related deaths using the Forensic Drug Data (FDD) and persons with opioid use disorder 
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in Medicaid claims data. To establish effective strategies to address WV opioid overdose 
problem, the first step is to have a comprehensive understanding of current opioid crisis. 
Secondly, since we do have evidence-based and appropriate clinical interventions and treatment 
models to prevent opioid overdose mortality (Wakeman 2019)10, MOUD, effective but not 
perfect, has not been systematically evaluated its effectiveness on WV population, the 
characteristics of which is quite different from other populations in the States. Lastly, there are 
some significant barriers existing in both scientific evidence gaps and medical resources gaps 
that keep West Virginia OUD patients from being treated. To answer the question that whether 
MOUD can be effective in reducing mortality, a survival approach was applied to quantitatively 
assess the association between time-dependent MOUD, recurrent non-fatal overdose events and 
the patients’ survival outcome, after controlling for patients’ demographics, comorbidities and 
prescriptions. To the best of our knowledge, the study is the first to comprehensively describe the 
current synthetic opioid problem, especially fentanyl and/or fentanyl analog-related death in 
WV. The study shed lights on profiling a full description of characteristics of overdose and OUD 
patients among WV Medicaid population, which is very valuable for future policy making and 
treatment improvement, along with the application of survival methodologies alongside an in 
depth investigation of MOUD effectiveness in a West Virginia Medicaid population. 
5.3 Future research 
The limitations of the current study, especially the small sample size and limited follow up 
period, indicate the need for more research to have a better understanding of how time-dependent 
MOUD and repeated overdoses affect people’s survival outcomes in West Virginia. First the 
generalizability of the study was largely constrained because of the short length of study follow-
up period, which only followed the cohort for 1 year as this was used in recently published 
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studies (Larochelle et al., 2018; Suffoletto and Zeigler et al., 2020)11,13 and we only had 3 years 
of data and more years of data has only recently become available. Studies applying survival 
approaches usually have a follow up period over three years to reach a decent sample size and 
statistical power, therefore, another two to three years data are needed for a comprehensive study 
in WV as the state only had a small number of overdoses over the study period: 1703 compared 
to 17568 in the Massachusetts study (Larochelle et al., 2018)11. Moreover, with more years of 
Medicaid data available, we would be able to assess not just the one-year mortality rate but 
maybe three-year or five-year mortality rates, to evaluate the long-run survival outcome. Second, 
the study was unable to evaluate the effect of methadone on survival rates since methadone was 
not covered by WV Medicaid until recently in January 1, 2018. This is another essential reason 
why we need more recent years’ data to have a full evaluation of MOUD effectiveness. 
Methadone has been shown to be an effective treatment for OUD although some studies have 
shown varying effects on lowering patients’ mortality rates in  study settings, with some 
demonstrating  a significant decreased all-cause mortality as well as opioid-specific mortality 
(Larochelle et al., 2018; Sordo et al., 2017; Ahmadi et al., 2003)11,14,15, However some studies 
found that methadone was not as effective as buprenorphine and naltrexone (Larochelle et al., 
2016; Kelty and Hulse)16,17. It is of great importance to include this medication in the analysis to 
achieve a better understanding of the treatment effectiveness of all three medications in West 
Virginia. A third limitation is that the Medicaid data in the CDM we used does not include all 
patients in Medicaid as it already excluded persons with dual-eligibility with Medicare, which 
accounts for about 20% of overall Medicaid population. People with dual-eligibility include 
those aged under 65 with disabilities, and people of any age with End-Stage Renal Disease. 
When dual eligible beneficiaries have claims, Medicare pays first and Medicaid pays last so only 
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limited claims data are available in Medicaid for these people. According to the findings from 
our study, older age (over 44) population were at elevated risk of all-cause mortality. Additional 
data linkage with Medicare to have access to the claim data would be a necessary step to have 
full evaluation of overall WV Medicaid population. The elderly population in West Virginia 
were believed to have higher rates of opioid prescriptions and benzodiazepine prescriptions, 
which lead to other drug-related comorbidities or psychiatric conditions (Peirce et al., 2012)18.   
To curb the opioid overdose from a larger scope and advancing with the times, poly-substance 
use and poly-substance induced overdose are key factors that needed for additional studies. 
There were emerging methamphetamine-related deaths in West Virginia and many of them were 
mixed using with opioids (Kariisa set al., 2019)19. Additional studies should focus on developing 
the treatment tailored for increasing numbers of mixed opioid and stimulant users (Ellis et al., 
2018)20.  
5.4 Conclusions 
With drastically increasing numbers of both non-fatal overdoses and fatal overdoses, 
understanding the risk of repeated overdose and the value of receiving appropriate MOUD in 
time is essential to prevent deaths. The findings from this study confirmed the contribution of 
continuous efforts by state agencies to expand Medicaid eligibility and MOUD access. That 
being said, the state is facing an increasingly critical opioid overdose situation, as well as 
opportunities to initiate treatment to curb the rise in fatal and non-fatal overdoses. Moreover, the 
findings of this study underscore the need for good compliance of patients staying in the 
treatment rather than in and out intermittently, leading to increased risk of relapse and mortality. 
The study results inform necessary policy change to guarantee that any patients who are 
receiving MOUD are able to finish the treatment regardless the change of eligibility status. 
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Furthermore, in order to reach a better treatment effect, additional primary care services to 
address comorbidities along with social support are needed to prevent relapse, which would 
otherwise waste all the previous efforts. 
In conclusion, this study suggests that MOUD is likely to be effective in lowering mortality risk 
in West Virginia, however, limited sample size prevented us from reaching sufficient statistical 
power. The new data has just became available, and with more recent years’ data, we are 
planning to expand the study years to determine how effective MOUD is in lowering both all-
cause mortality and opioid-specific mortality and evaluate the impact of poor compliance to the 
treatment, resulting in compromised treatment effectiveness. More future research are needed to 
guide the timely receipt of MOUD for the patients in urgent need. The state agencies should 
consider necessary policy change to expand treatment access, Medicaid eligibility, and also 
provide people who had opioid overdoses to receive comprehensive and effective treatments and 
supports. 
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APPENDIX A DIAGNOSTIC CODES USED IN ANALYSIS  
Diagnostic codes used for opioid overdoses recorded in the West Virginia Medicaid 
Type of overdose ICD-9 ICD-10 
Opioid overdose 
hospitalization 
965.00 (Opium) T40.0X Opium  
965.01 (Heroin) T40.1X Heroin 
965.02  (Methadone) T40.2X Other opioids 
965.09 (Other opiates/narcotics)  T40.3X Methadone 
E850.0 (Accidental: Heroin T40.4X Synthetic narcotics 
E850.1 (Accidental: Methadone) T40.60X Unspecified narcotics 
E850.2 (Accidental: Other opiates) T40.69X Other narcotics 
Opioid overdose 
mortality   
X40-X44 (accidental)  
X60-X64 (intentional/self-harm) 
X85 (assault/homicide) 
Y10-Y14 (undetermined) 
With a contribution cause of 
death code T40.0-T40.4, T40.6 
Opioid use disorder 
304.0 Opioid dependence F11.1 Opioid abuse 
305.5 Opioid abuse F11.2 Opioid dependence 
  F11.9 Opioid use 
 
Cancer Diagnosis Codes 
Subjects were categorized as having cancer in the Medicaid data if they had one or more claims 
in calendar years 2014-2016 with one of the following ICD-9 or ICD-10 diagnosis codes: 
• ICD-9 Codes: 140.X-165.X, 170.X-172.X, 174.X-175.X, 179-203.X, 238.6, 273.3, V10.X 
• ICD-10 Codes: C00.X-C26.X, C30.X-C34.X, C37.X-C41.X, C43.X, C47.8, C48.X-C58, 
C60.XC73, C75.X-C85.X, C88.X, C90.X, C96.X, D03.X, D47.Z9, Z85.X 
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Appendix B Variables of Interest 
Characteristics Variables Values or Related codes 
Age Age groups; categorical 
1: 18-29; 
2: 30-44; 
3: >= 45. 
Gender Sex; categorical 1: Male; 2: Female. 
Eligibility category Eligibility category; categorical 
1: Pregnant Women; 
2: Children; 
3: Disabled Adults; 
4: Non-Disabled Adults; 
5: Expansion Adults. 
Race Race, categorical 
1: Non-Hispanic white; 
2: Non-Hispanic black; 
3: Hispanic; 
4: Others. 
Psychiatric conditions   
  Anxiety anx (1=yes, 0=no) 
ICD*-9: 300; 
ICD-10: F40, F41 
  Depression dep (1=yes, 0=no) 
ICD-9: 296.2, 296.3, 
300.4, 311;I 
ICD-10: F32, F33, F34.1 
  Bipolar bip (1=yes, 0=no) 
ICD-9: 296.0, 296.1, 
296.4, 296.5, 296.6, 296.7, 
296.8; 
ICD-10: F31 
  Alcohol use disorder alc (1=yes, 0=no) 
ICD-9: 303; 
ICD-10: F10 
  Drug use disorder dru (1=yes, 0=no) 
ICD-9: 292, 304, 305; 
ICD-10: F12-F19 
  Opioid use disorder oud (1=yes, 0=no) 
ICD-9 codes: 304.0, 304.7, 
305.5; 
ICD-10 codes: F11 
Medication for opioid use disorder (MOUD)  
Any receipt of MOUD moud (1=yes, 0=no)  
Receipt of MOUD at baseline moudbaseline (1=yes, 0=no)  
Duration in MOUD over 88 days duration (1=yes, 0=no)   
  Naltrexone  
The Healthcare Common 
Procedure Coding System 
(HCPCS): J2315; 
National Drug Code 
(NDC):  
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00406117001, 
00406117003, 
16729008101, 
16729008110, 
47335032683, 
47335032688, 
51224020630, 
51224020650, 
68084029121, 
68094085362 
  Buprenorphine Hydrochloride  
HCPCS: J0592; 
NDC:  
00054017613, 
00054017713, 
00054018813, 
00054018913, 
00228315303, 
00228315473, 
00228315573, 
00228315603, 
00378092393, 
00378092493, 
50383028793, 
50383092493, 
50383093093, 
65162041503, 
65162041603  
  Suboxone  
HCPCS: J0571-0575; 
NDC:  
12496120201, 
12496120203, 
12496120401, 
12496120403, 
12496120801, 
12496120803, 
12496121201, 
12496121203 
 
